var title_f9_18_9504="Bullous lupus";
var content_f9_18_9504=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F66048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F66048&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bullous lupus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A young woman with systemic lupus erythematosus developed bullous eruptions on her arms and hands. Skin biopsy confirmed that this was SLE, not pemphigus or pemphigoid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Peter H Schur, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9504=[""].join("\n");
var outline_f9_18_9504=null;
var title_f9_18_9505="Mechanism glucocorticoid action";
var content_f9_18_9505=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F67246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F67246&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 616px\">",
"   <div class=\"ttl\">",
"    Mechanisms of glucocorticoid receptor action",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 596px; height: 444px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Glucocorticoids (GC) cross freely into the cytoplasm where they bind to and activate the glucocorticoid receptor (GR). Activated GR translocates into the nucleus where it can bind as a dimer to a glucocorticoid response element (GRE) and induce the expression of anti-inflammatory genes such as the IL-10",
"    <sup>",
"     [1]",
"    </sup>",
"    . This involves a change in local histone acetylation status and chromatin remodelling. Secondly, the GR dimer can bind to a negative GRE to prevent inflammatory gene expression preventing formation of an active transcriptional complex",
"    <sup>",
"     [2]",
"    </sup>",
"    . Thirdly, GR, acting as a monomer, binds directly or indirectly with pro-inflammatory transcription factors such as nuclear factor kappaB (NF-kappaB) preventing its ability to switch on inflammatory gene expression",
"    <sup>",
"     [3]",
"    </sup>",
"    . The increased expression of the GRbeta isoform found in some patients with glucocorticoid insensitive severe asthma can act as a dominant negative regulator of GRalpha",
"    <sup>",
"     [4]",
"    </sup>",
"    .",
"    <div class=\"footnotes\">",
"     MKP-1:&nbsp;mitogen-activated protein kinase phosphatase-1.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Jagirdar J, Begin R, Dufresne A, et al. Transforming growth factor-beta (TGF-beta) in silicosis. Am J Respir Crit Care Med 1996; 154:1076.",
"      </li>",
"      <li>",
"       Saatcioglu F, Claret FX, Karin M. Negative transcriptional regulation by nuclear receptors. Semin Cancer Biol 1994; 5:347.",
"      </li>",
"      <li>",
"       Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR. Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 1990; 249:1266.",
"      </li>",
"      <li>",
"       Stauber C, Altschmied J, Akerblom IE, et al. Mutual cross-interference between glucocorticoid receptor and CREB inhibits transactivation in placental cells. New Biol 1992; 4:527.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9505=[""].join("\n");
var outline_f9_18_9505=null;
var title_f9_18_9506="Pulmonary hypertension four chamber echocardiogram";
var content_f9_18_9506=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/55501/4chpulhy_conv.mp4?title=Pulmonary+hypertension+four+chamber+echocardiogram\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary hypertension four chamber echocardiographic view",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 225px; height: 411px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The four chamber view from a 2-D echocardiogram shows marked enlargement of the right atrium and ventricle which is also hypokinetic as a result of elevated pressures due to pulmonary hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9506=[""].join("\n");
var outline_f9_18_9506=null;
var title_f9_18_9507="Adapalene and benzoyl peroxide: Drug information";
var content_f9_18_9507=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Adapalene and benzoyl peroxide: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?12/2/12324?source=see_link\">",
"    see \"Adapalene and benzoyl peroxide: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6865472\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Epiduo&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F12931923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tactuo&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6870706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Acne Products;",
"     </li>",
"     <li>",
"      Topical Skin Product;",
"     </li>",
"     <li>",
"      Topical Skin Product, Acne",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6870730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Acne vulgaris:",
"     </b>",
"     Topical: Apply once daily to affected areas after skin has been cleaned and dried",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F6870729\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;9 years and Adolescents: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6870731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6870735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gel, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Epiduo&reg;: Adapalene 0.1% and benzoyl peroxide 2.5% (45 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6870704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6870732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply a pea-sized amount for each area of the face (eg, forehead, chin, each cheek). Skin should be clean and dry before applying. For external use only; avoid applying to eyes and mucous membranes.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6870707\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of acne vulgaris",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6870716\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%: Dermatologic: Dry skin (&lt;1% to 10%), scaling (&lt;1% to 9%), erythema (1% to 8%), burning (1% to 7%), stinging (1% to 7%), contact dermatitis (3%), skin irritation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Postmarketing and/or case reports: Blistering, conjunctivitis, eczema, eyelid edema, facial swelling, pain, photosensitivity, pruritus, rash, skin discoloration",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6870712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6870713\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Bleaching effects: May bleach hair or colored fabric.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Photosensitivity: Use is associated with increased susceptibility/sensitivity to UV light; avoid sunlamps or excessive sunlight exposure. Daily sunscreen use and other protective measures are recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Skin irritation: Certain cutaneous signs and symptoms (eg, erythema, dryness, scaling, burning/stinging) may occur during treatment; these are most likely to occur during the first 4 weeks and usually lessen with continued use. Use of moisturizer, decreased use, or discontinuation may be recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Topical acne product: Use concomitant topical acne therapy with caution; cumulative irritancy may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Appropriate use: For external use only; avoid contact with abraded skin, mucous membranes, and eyes.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F7273066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Contraceptives (Progestins): Retinoic Acid Derivatives may diminish the therapeutic effect of Contraceptives (Progestins). Retinoic Acid Derivatives may decrease the serum concentration of Contraceptives (Progestins).  Management: Two forms of effective contraception should be used in patients receiving retinoic acid derivatives.  Particularly, microdosed progesterone-only preparations may be inadequately effective.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoic Acid Derivatives.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the adverse/toxic effect of Retinoid-like Compounds.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin A: May enhance the adverse/toxic effect of Retinoid-like Compounds.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6870708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6870709\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no well-controlled studies in pregnant women. Use only if benefit outweighs the potential risk to fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6870711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16321919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Epiduo External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.1-2.5% (45 g): $307.86",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F10961947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Epiduo (AR, AU, BE, BR, CH, CO, DE, DK, FI, FR, GB, HK, IE, IT, KP, MY, NO, NZ, PH, PL, PT, SE, SG, TH)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6870721\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzoyl peroxide releases free-radical oxygen which oxidizes bacterial proteins in the sebaceous follicles decreasing the number of anaerobic bacteria and decreasing irritating-type free fatty acids.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adapalene is a retinoid-like compound which is a modulator of cellular differentiation, keratinization, and inflammatory processes, all of which represent important features in the pathology of acne vulgaris.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6870723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Via the skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Benzoyl peroxide: Converted to benzoic acid in skin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Adapalene: Primarily through bile; Benzoyl peroxide: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9009 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-200.215.4.194-84581B2B62-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9507=[""].join("\n");
var outline_f9_18_9507=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6865472\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12931923\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870706\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870730\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870729\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870731\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870735\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870704\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870732\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870707\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870716\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870712\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870713\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298687\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F7273066\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870708\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870709\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870711\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16321919\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10961947\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870721\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6870723\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9009\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9009|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?12/2/12324?source=related_link\">",
"      Adapalene and benzoyl peroxide: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_18_9508="Passive neck rotation";
var content_f9_18_9508=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64373&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 472px\">",
"   <div class=\"ttl\">",
"    Passive neck rotation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 452px; height: 435px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Loss of rotation is the universal sign of neck pathology. The patient is asked to relax. The examiner places one hand on the shoulder and one hand on the chin. The neck is passively rotated to the affected side and compared with rotation to the opposite side. Rotation less than 90 degrees is abnormal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9508=[""].join("\n");
var outline_f9_18_9508=null;
var title_f9_18_9509="Tuboovarian abscess";
var content_f9_18_9509=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60914&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tuboovarian abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross intraoperative photograph of a left tuboovarian abscess in a patient with pelvic inflammatory disease.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mitchel Hoffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9509=[""].join("\n");
var outline_f9_18_9509=null;
var title_f9_18_9510="Miliary nodules PA";
var content_f9_18_9510=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F68302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F68302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Miliary nodular pattern",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 381px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Standard International Labor Office film for small rounded opacities, 1.5 to 3 mm in diameter (miliary nodules).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Normal chest radiograph",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 371px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posteroanterior view of a normal chest radiograph.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol M Black, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9510=[""].join("\n");
var outline_f9_18_9510=null;
var title_f9_18_9511="Torsion with nonviable ovary";
var content_f9_18_9511=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F61891%7EOBGYN%2F72645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F61891%7EOBGYN%2F72645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Enlarged left ovary found torsed upon laparotomy demonstrating a dark, dusky appearance secondary to venous lymphatic congestion in the setting of continued arterial perfusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 373px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ovarian and tubal torsion demonstrating marked vascular engorgement as well as increased size and distension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomy was restored and both structures were salvaged despite non-viable appearance.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR, Goldstein DP (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9511=[""].join("\n");
var outline_f9_18_9511=null;
var title_f9_18_9512="Treatment of acute procedure anxiety in adults";
var content_f9_18_9512=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of acute procedure anxiety in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/18/9512/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/18/9512/contributors\">",
"     Yujuan Choy, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/18/9512/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/18/9512/contributors\">",
"     Murray B Stein, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/18/9512/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/18/9512/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/18/9512/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1822698\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute procedure anxiety is an excessive fear of medical, dental or surgical procedures that results in acute stress or avoidance. Patients may experience anxiety in anticipation of or during procedures used for screening (eg, mammography), diagnosis (eg, amniocentesis or endoscopy), and treatment (eg, angioplasty or major surgery). Avoidance of clinical procedures due to acute procedure anxiety can have negative health consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/1-7\">",
"     1-7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Specific phobias are a subset of the varied manifestations of acute procedure anxiety, diagnosed under DSM-IV-TR criteria only when the patient&rsquo;s fears are specific to the procedure and its immediate effects (eg, fear of suffocation during an MRI) rather than fears not specific to the procedure itself (eg, a fear of the underlying illness that might be diagnosed). Specific phobias related to clinical procedures include blood-injection-injury phobia, dental phobia, and MRI claustrophobia.",
"   </p>",
"   <p>",
"    This topic addresses the treatment of acute procedure anxiety that does not constitute a specific phobia. Treatment for specific phobias of clinical procedures (including blood-injection-injury phobia, dental phobia, and MRI claustrophobia) is addressed separately. The epidemiology, clinical manifestations, course, screening, assessment, and differential diagnosis of acute procedure anxiety are also discussed separately. The epidemiology, clinical manifestations, course, diagnosis, and treatment of other specific phobias are also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link\">",
"     \"Treatment for specific phobias of medical and dental procedures\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=see_link\">",
"     \"Acute procedure anxiety in adults: Epidemiology and clinical presentation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11782?source=see_link\">",
"     \"Acute procedure anxiety in adults: Course, screening, assessment, and differential diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=see_link\">",
"     \"Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link\">",
"     \"Psychotherapy for specific phobia in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=see_link\">",
"     \"Pharmacotherapy for specific phobia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1821648\">",
"    <span class=\"h1\">",
"     GENERAL TREATMENT PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several general principles can be useful in the management of acute procedure anxiety. Unless otherwise specified, these guidelines are based on our clinical experience.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Establish a trusting doctor-patient relationship &mdash; A trusted physician may be better able to explain to the patient why an indicated procedure is necessary, and to reassure him or her of its safety.",
"     </li>",
"     <li>",
"      Educate the patient about the procedure &mdash; Address any preconceived notions about the procedure and potential outcomes, and allow the patient to ask questions and bring up concerns [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/8-10\">",
"       8-10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H877180\">",
"       'Supplemental education'",
"      </a>",
"      below.)",
"      <strong>",
"      </strong>",
"     </li>",
"     <li>",
"      Determine what aspect of the procedure is most anxiety provoking for the patient &mdash; Directly address that underlying focus with the patient through acknowledgment and education.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Acknowledge the patient&rsquo;s anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/10\">",
"       10",
"      </a>",
"      ]",
"      <strong>",
"      </strong>",
"      and normalize the experience of anxiety if it is common, as is the case with invasive prenatal testing. Avoid telling patients not to worry as this will undermine their concerns and imply that they are able to stop their worries at will.",
"     </li>",
"     <li>",
"      Patients who are anxious tend to think of the worst negative outcome and overestimate the likelihood of the feared outcome [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      In mild cases of anxiety, providing accurate data and realistic evaluation of the risks may be sufficient to decrease anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Provide patients with as much control as possible during the procedure",
"      <strong>",
"       &mdash;",
"      </strong>",
"      This may include assuring the patient that nothing will happen during the procedure that is not agreed upon in advance.",
"      <strong>",
"      </strong>",
"      Allow the patient to interrupt or end the procedure if anxiety becomes intolerable, as long as it is safe to do so [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/9,10\">",
"       9,10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Make the patient as comfortable as possible during the procedure",
"      <strong>",
"       &mdash;",
"      </strong>",
"      Allow family members or friends to be present during the procedure if desired by the patient and not medically contraindicated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Evaluate whether treatment is needed &mdash; Mild cases of acute procedure anxiety may respond to verbal acknowledgment and correction of inaccurate assumptions about the procedure; however, moderate or severe anxiety may require intervention to reduce patient distress",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      to prevent avoidance of a necessary procedure. Individual treatments for acute procedure anxiety are described below.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7713871\">",
"    <span class=\"h1\">",
"     INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are both pharmacologic and psychotherapeutic options for treating acute procedure anxiety. Placebo-controlled clinical trials are mostly limited to the subset of presentations diagnosed as specific phobias of clinical procedures (ie, dental phobia, blood-injection-injury phobia, and MRI claustrophobia), the treatment of which is described separately. In the absence of clinical trials, selection among treatments for acute procedure anxiety that does not constitute a specific phobia is largely guided by clinical experience and the practical circumstances of a patient&rsquo;s procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link\">",
"     \"Treatment for specific phobias of medical and dental procedures\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among medications, we suggest use of a benzodiazepine first-line medication for acute procedure anxiety other than specific phobias. Among psychotherapies, we suggest first-line use of brief cognitive behavioral therapy. Indications for selecting between medication and psychotherapy are discussed later in this topic. (See",
"    <a class=\"local\" href=\"#H876428\">",
"     'Treatment selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876469\">",
"    <span class=\"h2\">",
"     Benzodiazepines",
"    </span>",
"    &nbsp;&mdash;&nbsp;To our knowledge there are no placebo-controlled clinical trials of benzodiazepines in acute procedure anxiety; however, treatment of acute procedure anxiety with benzodiazepines is common and, in our clinical experience, usually effective. Treatment with a benzodiazepine is used to induce anxiolysis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    sedation, allowing the patient to tolerate and complete the procedure.",
"   </p>",
"   <p>",
"    To achieve sedation in a patient with (or likely to experience) acute procedure anxiety, a benzodiazepine is typically administered intravenously 15 minutes prior to the procedure, or 30 minutes prior to the procedure for oral formulations.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     Diazepam",
"    </a>",
"    has a more rapid onset than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    . As an example, 10 mg of oral diazepam is recommended for healthy adults [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/12\">",
"     12",
"    </a>",
"    ]. A table provides dosing of oral and intravenous benzodiazepines commonly used in procedural sedation (",
"    <a class=\"graphic graphic_table graphicRef71754 \" href=\"UTD.htm?23/28/24012\">",
"     table 1",
"    </a>",
"    ). For these medications, the following adjustments to the usual adult dose are recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A 50 percent reduction is needed in adults older than 60",
"     </li>",
"     <li>",
"      A 50 percent dose reduction is needed for patients who are debilitated, have low cardiac output, or have been premedicated with opioid analgesics.",
"     </li>",
"     <li>",
"      No dose adjustment is needed with renal insufficiency",
"     </li>",
"     <li>",
"      A 50 percent reduction of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      in patients with hepatic insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/13\">",
"       13",
"      </a>",
"      ]. However,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      should be the drug of choice for patients with liver failure, because it undergoes glucuronide conjugation and its half-life is only slightly affected in hepatic dysfunction [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/13\">",
"       13",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Patients with acute procedure anxiety and concurrent regular benzodiazepine or alcohol use (or misuse, abuse, or dependence) may require a higher-than-usual dose of benzodiazepine to account for possible tolerance to the drug. A substance use disorder is generally not considered a contraindication to one-time use of a benzodiazepine for acute procedure anxiety as long as the patient is not acutely intoxicated with another sedating substance at the time of the procedure and the patient is closely monitored for respiratory depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Oral dosing may be repeated after 30 minutes to one hour, if the initial dose has no effect. Peak plasma level following oral administration is reached within 60 minutes for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"     diazepam",
"    </a>",
"    and within 120 minutes for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/13\">",
"     13",
"    </a>",
"    ]. As an example, in a study of procedural sedation prior to an MRI scan, about a quarter of the patients required a second medication dose because of either an inadequate response to the first dose or a prolonged procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients dependent on alcohol or benzodiazepines may require a higher benzodiazepine dose to achieve sedation. The pharmacology of these benzodiazepines is summarized in a table (",
"    <a class=\"graphic graphic_table graphicRef71754 \" href=\"UTD.htm?23/28/24012\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Intranasal administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    has shown efficacy for procedural sedation in two clinical trials of patients with MRI claustrophobia; both trials had methodologic limitations rendering the results preliminary [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The minimal effective dose is 1 mg with repeated doses of up to 4 mg as needed. Intranasal midazolam has a faster onset of action (within 15 minutes) compared to oral administration, is not affected by hepatic first-pass metabolism, and is more easily administered than intravenous medication. Intranasal midazolam is readily prepared and used in hospitals in US and other countries, especially those serving pediatric populations. The oral form of midazolam is almost never used due to widely variable efficacy. &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Patients should be educated about potential side effects of benzodiazepines, described separately, and outpatients should be warned against driving because of sedating effects and psychomotor impairment",
"    <strong>",
"     .",
"    </strong>",
"    The length of time to avoid driving depends on time for resolution of psychomotor impairment, which is affected by the dosage, route of administration and drug potency. Examples, based on studies of healthy volunteers, are provided below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=see_link&amp;anchor=H21#H21\">",
"     \"Treatment of insomnia\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       Diazepam",
"      </a>",
"      &mdash; Patients should not drive for at least five hours after oral administration of 10mg diazepam [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/16\">",
"       16",
"      </a>",
"      ] or intravenous administration of 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of diazepam [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/17\">",
"       17",
"      </a>",
"      ]. At higher intravenous doses of diazepam (0.30",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      or 0.45",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      patients should avoid driving for at least 10 hours [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"       Midazolam",
"      </a>",
"      &mdash; Patients should not drive for at least five hours after intravenous administration of midazolam at 0.1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/18\">",
"       18",
"      </a>",
"      ]. At higher doses of midazolam (0.15",
"      <span class=\"nowrap\">",
"       mg/kg),",
"      </span>",
"      residual psychomotor impairment persists at 5 hours.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       Lorazepam",
"      </a>",
"      &mdash; Patients should refrain from driving for up to 24 hours after an oral dose of 2.5 mg lorazepam [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients should be evaluated to ensure that they are safe to leave and should only be discharged if accompanied by a companion [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=see_link&amp;anchor=H31#H31\">",
"     \"Depression in pregnant women: Management\", section on 'Benzodiazepines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=see_link&amp;anchor=H20#H20\">",
"     \"Use of psychotropic medications in breastfeeding women\", section on 'Benzodiazepines'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=see_link\">",
"     \"Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87642297\">",
"    <span class=\"h2\">",
"     Brief cognitive-behavioral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is a form of psychotherapy that incorporates cognitive and behavioral interventions to reduce symptoms of acute procedure anxiety. Components of CBT include psychoeducation, cognitive restructuring, exposure therapy,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    relaxation training. The goal of cognitive restructuring is to gain a more realistic perspective of the procedure by changing maladaptive or irrational thought patterns that are associated with anxious feelings. Behavioral interventions, such as exposure or relaxation training, are used to reduce symptoms or overcome avoidance of a procedure. These interventions may be used together, or may be applied selectively based on the patient&rsquo;s clinical presentation. A brief CBT, delivered over two to four sessions, can be used for acute procedure anxiety, though support for the duration is limited to the single trial that follows.",
"   </p>",
"   <p>",
"    A single trial evaluated the efficacy of brief CBT consisting of psychoeducation, cognitive restructuring, and a behavioral intervention in reducing anxiety and depression among patients awaiting coronary artery bypass graft surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/20\">",
"     20",
"    </a>",
"    ]. One hundred preoperative patients were randomly assigned to four, 60-minute sessions of CBT or to treatment as usual. The intervention group experienced reduced symptoms of anxiety and depression after the intervention and at three to four weeks post-discharge compared to the treatment-as-usual group. Patients receiving CBT also experienced more improvement in quality of life and a shorter hospital stay (7.9 days versus 9.2 days).",
"   </p>",
"   <p>",
"    Numerous trials have found cognitive behavioral therapy to be an effective treatment for specific anxiety disorders, including generalized anxiety disorder, panic disorder, social anxiety disorder, posttraumatic stress disorder and obsessive compulsive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=see_link&amp;anchor=H15673212#H15673212\">",
"     \"Psychotherapy for generalized anxiety disorder\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=see_link&amp;anchor=H10265636#H10265636\">",
"     \"Psychotherapy for obsessive-compulsive disorder\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=see_link&amp;anchor=H157308639#H157308639\">",
"     \"Psychotherapy for panic disorder\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=see_link&amp;anchor=H1118664160#H1118664160\">",
"     \"Psychotherapy for posttraumatic stress disorder\", section on 'Cognitive and behavioral therapies'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=see_link&amp;anchor=H384601236#H384601236\">",
"     \"Psychotherapy for social anxiety disorder\", section on 'Cognitive behavioral therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Individual components of CBT for acute procedure anxiety are described further below. In addition to clinical trials of combined cognitive and behavioral interventions (above), some component interventions have been tested as monotherapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393965\">",
"    <span class=\"h3\">",
"     Psychoeducation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT begins with education on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reason the procedure was recommended, knowledge about the procedure, what to expect during the procedure and potential outcomes",
"     </li>",
"     <li>",
"      Factors leading to anxiety and avoidance of clinical procedures",
"     </li>",
"     <li>",
"      Physiologic symptoms that may accompany the anxiety",
"     </li>",
"     <li>",
"      Treatment plan and rationale",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393775\">",
"    <span class=\"h3\">",
"     Cognitive restructuring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive restructuring involves the identification and modification of overly negative cognitions regarding an anxiety-inducing clinical procedure. Cognitive restructuring has not been widely tested as monotherapy in acute procedure anxiety. A single trial of 52 patients did not find the intervention to effectively reduce symptoms of dental phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link&amp;anchor=H607337143#H607337143\">",
"     \"Treatment for specific phobias of medical and dental procedures\", section on 'Cognitive restructuring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393630\">",
"    <span class=\"h3\">",
"     Exposure therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In exposure therapy, the patient gradually confronts the anxiety-inducing procedure in a safe and controlled manner [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/23\">",
"     23",
"    </a>",
"    ]. This is preferably done in real-world situations, which is referred to as in-vivo exposure, but can also be performed using pictures, narrative,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    memory in imaginal exposure.",
"   </p>",
"   <p>",
"    Exposure therapy has not been widely tested as monotherapy for acute procedure anxiety. Trials have found exposure therapy to be efficacious in the treatment of dental phobia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link&amp;anchor=H607337122#H607337122\">",
"     \"Treatment for specific phobias of medical and dental procedures\", section on 'Dental phobia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link\">",
"     \"Psychotherapy for specific phobia in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although more time consuming to administer than a sedating medication, the benefit of exposure therapy may last for months to years following treatment, while a sedating medication&rsquo;s clinical effects are limited to the period immediately following their administration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=see_link&amp;anchor=H6645415#H6645415\">",
"     \"Psychotherapy for specific phobia in adults\", section on 'Exposure therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link&amp;anchor=H607337192#H607337192\">",
"     \"Treatment for specific phobias of medical and dental procedures\", section on 'Duration of treatment effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H393989\">",
"    <span class=\"h3\">",
"     Relaxation training",
"    </span>",
"    &nbsp;&mdash;&nbsp;Teaching patients relaxation exercises can address the elevated muscle tension and reduced flexibility of autonomic functioning that often accompanies anxiety [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/25\">",
"     25",
"    </a>",
"    ]. In relaxation training, patients are typically trained to systematically relax different muscle groups until proficiency is achieved in relaxation of the whole body on cue [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H877180\">",
"    <span class=\"h2\">",
"     Supplemental education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several clinical trials have tested whether supplemental education (ie, providing information beyond that routinely provided in the informed consent process) reduced acute procedure anxiety prior to or during clinical procedures, but findings have been mixed [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/27-34\">",
"     27-34",
"    </a>",
"    ]. Supplemental education has been found to be helpful in increasing patients&rsquo; knowledge about a procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. Variability in the trials (in the procedures studied, the mode of information delivery, the content and amount of information) as well as the methodologic shortcomings of the trials limit the conclusions that can be drawn. Examples of the trials are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a study of 140 patients undergoing endoscopy, patients who were provided with additional detailed written and verbal information related to the procedure reported a lower mean anxiety level compared to patients in usual care who received brief information about the procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In a study of 200 women undergoing colposcopy with high pre-procedure anxiety, there was no difference in anxiety level between women who were provided with an information leaflet prior to their appointment versus women who did not receive the leaflet [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      In two studies of patients undergoing first-time colposcopy, patients who attended a nurse-led educational session and received educational material before their colposcopy procedure were found to be no less anxious than patients who received the educational material alone [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/27,28\">",
"       27,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In 135 patients undergoing cardiac surgery, an intervention, consisting of 15 minutes of supplemental education and an opportunity to ask questions, reduced anxiety post-surgery compared to patients who received usual care [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/33\">",
"       33",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Single trials additionally suggest that supplemental education provided to patients prior to a procedure should:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Avoid excessive detail about potential complications of the procedure, as this may increase anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Provide education specific to the procedure and the patients&rsquo; clinical condition rather than more general material on the condition and its treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There has been little study comparing modes of information delivery in supplemental education. A single trial of 132 women undergoing colposcopy found that presenting information about the procedure via a video resulted in lower anxiety levels than presenting similar information in a written format [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H877209\">",
"    <span class=\"h2\">",
"     Music therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials have found music to reduce anxiety levels in samples drawn from patients awaiting clinical procedures (ie, not from patients with acute procedure anxiety). In these trials, music was played during a 15 to 20 minute interval prior to the procedure",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    during the procedure if sedation was not used [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. Music did not show a benefit in a trial of patients under conscious sedation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H877539\">",
"    <span class=\"h2\">",
"     Video observation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Video observation of a laparoscopic procedure allows the patient to view live video images of the procedure on a monitor, providing the same view that the physician has through the laparoscope. Video observation for the purpose of anxiety reduction has not been tested in patients with acute procedure anxiety. A trial was conducted of video observation for 81 women undergoing colposcopy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/42\">",
"     42",
"    </a>",
"    ]. The trial found that, compared to a control condition, video observation reduced anxiety and pain among women undergoing a diagnostic colposcopy, but not among women undergoing colposcopy that included laser treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H876428\">",
"    <span class=\"h1\">",
"     TREATMENT SELECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Based on the data described above and our clinical experience, either benzodiazepines or brief cognitive behavioral therapy (CBT) can be used first-line to treat acute procedure anxiety. There are no rigorous clinical trials comparing the efficacy of these interventions in acute procedure anxiety. Principles to guide the selection between them are described below.",
"   </p>",
"   <p>",
"    Medication treatment of acute procedure anxiety is indicated over psychotherapy under one or more of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient prefers treatment with medication over psychotherapy therapy.",
"     </li>",
"     <li>",
"      CBT is not available because of financial limitations or the unavailability of trained therapists.",
"     </li>",
"     <li>",
"      A procedure is needed on a rare or emergent basis.",
"     </li>",
"     <li>",
"      The patient&rsquo;s anxiety is so severe that the patient cannot tolerate CBT.",
"     </li>",
"     <li>",
"      The patient has previously failed an adequate trial of CBT.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Psychotherapy for acute procedure anxiety is indicated over medication under one or more of the following circumstances:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient prefers psychotherapy to medication.",
"     </li>",
"     <li>",
"      The patient is not able to tolerate medication or has medical contraindications to it.",
"     </li>",
"     <li>",
"      The patient requires a procedure on a repeated basis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1704501\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who are anxious tend to think of the worst negative outcomes and overestimate their likelihood [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/11\">",
"       11",
"      </a>",
"      ].",
"      <strong>",
"      </strong>",
"      In mild cases of acute procedure anxiety, providing accurate data and realistic evaluation of the risks is often sufficient to decrease anxiety [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9512/abstract/10\">",
"       10",
"      </a>",
"      ]. Moderate or severe anxiety may require intervention with medication or psychotherapy to reduce distress or overcome avoidance. (See",
"      <a class=\"local\" href=\"#H1821648\">",
"       'General treatment principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link&amp;anchor=H607336126#H607336126\">",
"       \"Treatment for specific phobias of medical and dental procedures\", section on 'General treatment principles'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      There is an absence of clinical trials on treatment of acute procedure anxiety other than treatment for specific phobias of clinical procedures (ie, dental phobia, blood-injection-injury phobia, and MRI claustrophobia). Thus, treatment decisions in acute procedure anxiety are guided by our clinical experience, the practical circumstances of a patient&rsquo;s procedure, and evidence from trials of other anxiety disorders. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link\">",
"       \"Treatment for specific phobias of medical and dental procedures\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      First-line treatment options for acute procedure anxiety include medications and psychotherapy. Treatment for specific phobias of clinical procedures (ie, dental phobia, blood-injection-injury phobia, and MRI claustrophobia) is discussed separately. (See",
"      <a class=\"local\" href=\"#H1821648\">",
"       'General treatment principles'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=see_link\">",
"       \"Treatment for specific phobias of medical and dental procedures\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Medication is indicated over psychotherapy in acute procedure anxiety that does not constitute a specific phobia under the following circumstances (See",
"      <a class=\"local\" href=\"#H876428\">",
"       'Treatment selection'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is preferred by the patient",
"     </li>",
"     <li>",
"      Cognitive behavioral therapy (CBT) is unavailable",
"     </li>",
"     <li>",
"      The procedure is needed on a one-time or emergent basis",
"     </li>",
"     <li>",
"      The patient&rsquo;s anxiety is too severe to tolerate CBT",
"     </li>",
"     <li>",
"      The patient previously failed an adequate trial of CBT",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For these patients, we suggest use of a benzodiazepine (",
"      <a class=\"graphic graphic_table graphicRef71754 \" href=\"UTD.htm?23/28/24012\">",
"       table 1",
"      </a>",
"      ) over other medications (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). As an example,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/46/16105?source=see_link\">",
"       diazepam",
"      </a>",
"      10 mg can be given intravenously approximately 15 minutes before the procedure, or orally approximately 25 minutes before the procedure, and repeated if needed after 30 to 60 minutes. (See",
"      <a class=\"local\" href=\"#H876469\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Psychotherapy is indicated over medication in acute procedure anxiety that does not constitute a specific phobia under the following circumstances (See",
"      <a class=\"local\" href=\"#H876428\">",
"       'Treatment selection'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      It is preferred by the patient",
"     </li>",
"     <li>",
"      The patient is not able to tolerate the medication or has medical contraindications to its use",
"     </li>",
"     <li>",
"      The patient requires a procedure on a repeated basis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For these patients, we suggest use of brief CBT over other psychotherapies (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H87642297\">",
"       'Brief cognitive-behavioral therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/1\">",
"      Page AC. Blood-injury-injection fears in medical practice. Med J Aust 1996; 164:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/2\">",
"      Lilliecreutz C, Sydsj&ouml; G, Josefsson A. Obstetric and perinatal outcomes among women with blood- and injection phobia during pregnancy. J Affect Disord 2011; 129:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/3\">",
"      Doerr PA, Lang WP, Nyquist LV, Ronis DL. Factors associated with dental anxiety. J Am Dent Assoc 1998; 129:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/4\">",
"      Poulton R, Thomson WM, Brown RH, Silva PA. Dental fear with and without blood-injection fear: implications for dental health and clinical practice. Behav Res Ther 1998; 36:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/5\">",
"      Elter JR, Strauss RP, Beck JD. Assessing dental anxiety, dental care use and oral status in older adults. J Am Dent Assoc 1997; 128:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/6\">",
"      Zambanini A, Newson RB, Maisey M, Feher MD. Injection related anxiety in insulin-treated diabetes. Diabetes Res Clin Pract 1999; 46:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/7\">",
"      Bienvenu OJ, Eaton WW. The epidemiology of blood-injection-injury phobia. Psychol Med 1998; 28:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/8\">",
"      Betti S, Sironi A, Saino G, et al. Effect of the informed consent process on anxiety and comprehension of patients undergoing esophageal and gastrointestinal surgery. J Gastrointest Surg 2011; 15:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/9\">",
"      Weinreb JC, Maravilla KR, Peshock R, Payne J. Magnetic resonance imaging: improving patient tolerance and safety. AJR Am J Roentgenol 1984; 143:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/10\">",
"      De Jongh A, Adair P, Meijerink-Anderson M. Clinical management of dental anxiety: what works for whom? Int Dent J 2005; 55:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/11\">",
"      Ost LG, Csatlos P. Probability ratings in claustrophobic patients and normal controls. Behav Res Ther 2000; 38:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/12\">",
"      Bluemke DA, Breiter SN. Sedation procedures in MR imaging: safety, effectiveness, and nursing effect on examinations. Radiology 2000; 216:645.",
"     </a>",
"    </li>",
"    <li>",
"     Mocromedex Healthcare Series [Internet database]. Greenwood Village, CO: Thomson Healthcare. Updated periodically.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/14\">",
"      Hollenhorst J, M&uuml;nte S, Friedrich L, et al. Using intranasal midazolam spray to prevent claustrophobia induced by MR imaging. AJR Am J Roentgenol 2001; 176:865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/15\">",
"      Tschirch FT, G&ouml;pfert K, Fr&ouml;hlich JM, et al. Low-dose intranasal versus oral midazolam for routine body MRI of claustrophobic patients. Eur Radiol 2007; 17:1403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/16\">",
"      Sepp&auml;l&auml; K, Korttila K, H&auml;kkinen S, Linnoila M. Residual effects and skills related to driving after a single oral administration of diazepam, medazepam or lorazepam. Br J Clin Pharmacol 1976; 3:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/17\">",
"      Korttila K, Linnoila M. Recovery and skills related to driving after intravenous sedation: dose-response relationship with diazepam. Br J Anaesth 1975; 47:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/18\">",
"      Nuotto EJ, Korttila KT, Lichtor JL, et al. Sedation and recovery of psychomotor function after intravenous administration of various doses of midazolam and diazepam. Anesth Analg 1992; 74:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/19\">",
"      Berlin L. Sedation and analgesia in MR imaging. AJR Am J Roentgenol 2001; 177:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/20\">",
"      Dao TK, Youssef NA, Armsworth M, et al. Randomized controlled trial of brief cognitive behavioral intervention for depression and anxiety symptoms preoperatively in patients undergoing coronary artery bypass graft surgery. J Thorac Cardiovasc Surg 2011; 142:e109.",
"     </a>",
"    </li>",
"    <li>",
"     Clark DA, Beck AT. Cognitive Therapy of Anxiety Disorders: Science and practice, Guilford Press, New York 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/22\">",
"      de Jongh A, Muris P, ter Horst G, et al. One-session cognitive treatment of dental phobia: preparing dental phobics for treatment by restructuring negative cognitions. Behav Res Ther 1995; 33:947.",
"     </a>",
"    </li>",
"    <li>",
"     Moscovitch DA, Antony MM, Swinson RP. Exposure-based treatments for anxiety disorders: Theory and process, Oxford University Press, New York 2009. p.461.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/24\">",
"      Wolitzky-Taylor KB, Horowitz JD, Powers MB, Telch MJ. Psychological approaches in the treatment of specific phobias: a meta-analysis. Clin Psychol Rev 2008; 28:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/25\">",
"      Thayer JF, Friedman BH, Borkovec TD. Autonomic characteristics of generalized anxiety disorder and worry. Biol Psychiatry 1996; 39:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/26\">",
"      Ost LG. Applied relaxation: description of a coping technique and review of controlled studies. Behav Res Ther 1987; 25:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/27\">",
"      Byrom J, Clarke T, Neale J, et al. Can pre-colposcopy sessions reduce anxiety at the time of colposcopy? A prospective randomised study. J Obstet Gynaecol 2002; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/28\">",
"      Chan YM, Lee PW, Ng TY, Ngan HY. Could precolposcopy information and counseling reduce women's anxiety and improve knowledge and compliance to follow-up? Gynecol Oncol 2004; 95:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/29\">",
"      de Bie RP, Massuger LF, Lenselink CH, et al. The role of individually targeted information to reduce anxiety before colposcopy: a randomised controlled trial. BJOG 2011; 118:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/30\">",
"      Marteau TM, Kidd J, Cuddeford L. Reducing anxiety in women referred for colposcopy using an information booklet. Br J Health Psychology 1996; 1:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/31\">",
"      Kutlut&uuml;rkan S, G&ouml;rg&uuml;l&uuml; U, Fesci H, Karavelioglu A. The effects of providing pre-gastrointestinal endoscopy written educational material on patients' anxiety: a randomised controlled trial. Int J Nurs Stud 2010; 47:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/32\">",
"      Chan DS, Cheung HW. The effects of education on anxiety among Chinese patients with heart disease undergoing cardiac catheterization in Hong Kong. Contemp Nurse 2003; 15:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/33\">",
"      Guo P, East L, Arthur A. A preoperative education intervention to reduce anxiety and improve recovery among Chinese cardiac patients: a randomized controlled trial. Int J Nurs Stud 2012; 49:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/34\">",
"      Howells RE, Dunn PD, Isasi T, et al. Is the provision of information leaflets before colposcopy beneficial? A prospective randomised study. Br J Obstet Gynaecol 1999; 106:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/35\">",
"      Uzbeck M, Quinn C, Saleem I, et al. Randomised controlled trial of the effect of standard and detailed risk disclosure prior to bronchoscopy on peri-procedure anxiety and satisfaction. Thorax 2009; 64:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/36\">",
"      Freeman-Wang T, Walker P, Linehan J, et al. Anxiety levels in women attending colposcopy clinics for treatment for cervical intraepithelial neoplasia: a randomised trial of written and video information. BJOG 2001; 108:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/37\">",
"      El-Hassan H, McKeown K, Muller AF. Clinical trial: music reduces anxiety levels in patients attending for endoscopy. Aliment Pharmacol Ther 2009; 30:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/38\">",
"      Hayes A, Buffum M, Lanier E, et al. A music intervention to reduce anxiety prior to gastrointestinal procedures. Gastroenterol Nurs 2003; 26:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/39\">",
"      L&oacute;pez-Cepero Andrada JM, Amaya Vidal A, Castro Aguilar-Tablada T, et al. Anxiety during the performance of colonoscopies: modification using music therapy. Eur J Gastroenterol Hepatol 2004; 16:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/40\">",
"      Chan YM, Lee PW, Ng TY, et al. The use of music to reduce anxiety for patients undergoing colposcopy: a randomized trial. Gynecol Oncol 2003; 91:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/41\">",
"      Stermer E, Levy N, Beny A, et al. Ambience in the endoscopy room has little effect on patients. J Clin Gastroenterol 1998; 26:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9512/abstract/42\">",
"      Walsh JC, Curtis R, Mylotte M. Anxiety levels in women attending a colposcopy clinic: a randomised trial of an educational intervention using video colposcopy. Patient Educ Couns 2004; 55:247.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16851 Version 2.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-211.167.112.15-CF2E8830EA-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9512=[""].join("\n");
var outline_f9_18_9512=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1704501\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1822698\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1821648\">",
"      GENERAL TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7713871\">",
"      INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H876469\">",
"      Benzodiazepines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H87642297\">",
"      Brief cognitive-behavioral therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393965\">",
"      - Psychoeducation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393775\">",
"      - Cognitive restructuring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393630\">",
"      - Exposure therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H393989\">",
"      - Relaxation training",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H877180\">",
"      Supplemental education",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H877209\">",
"      Music therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H877539\">",
"      Video observation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H876428\">",
"      TREATMENT SELECTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1704501\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/16851\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/16851|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/28/24012\" title=\"table 1\">",
"      Common benzodiazepines for treatment of procedural anxiety",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/32/11782?source=related_link\">",
"      Acute procedure anxiety in adults: Course, screening, assessment, and differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/39/9849?source=related_link\">",
"      Acute procedure anxiety in adults: Epidemiology and clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/0/28682?source=related_link\">",
"      Depression in pregnant women: Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/41/6806?source=related_link\">",
"      Pharmacotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/1/20505?source=related_link\">",
"      Psychotherapy for generalized anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34391?source=related_link\">",
"      Psychotherapy for obsessive-compulsive disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40297?source=related_link\">",
"      Psychotherapy for panic disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/58/5032?source=related_link\">",
"      Psychotherapy for posttraumatic stress disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/36/32327?source=related_link\">",
"      Psychotherapy for social anxiety disorder",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/59/25527?source=related_link\">",
"      Psychotherapy for specific phobia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/42/24232?source=related_link\">",
"      Sedatives and hypnotics abuse and dependence: Pharmacology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/24/22921?source=related_link\">",
"      Specific phobia in adults: Epidemiology, clinical manifestations, course and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/0/26632?source=related_link\">",
"      Treatment for specific phobias of medical and dental procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13290?source=related_link\">",
"      Treatment of insomnia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38745?source=related_link\">",
"      Use of psychotropic medications in breastfeeding women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_18_9513="Reproductive surgery for female infertility";
var content_f9_18_9513=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Reproductive surgery for female infertility",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/18/9513/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/18/9513/contributors\">",
"     Togas Tulandi, MD, MHCM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/18/9513/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/18/9513/contributors\">",
"     Tommaso Falcone, MD, FRCSC, FACOG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/18/9513/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/18/9513/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/18/9513/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The availability of assisted reproductive technology has reduced the need for reproductive surgery as a primary surgical treatment of infertility. When fertility surgery is indicated, operative laparoscopy results in outcomes as good as those from similar procedures performed via open laparotomy and is associated with a shorter hospital stay, lower incidence of ileus, and faster recovery. In addition, there is less contamination of the surgical field with glove powder or lint, bleeding is reduced due to tamponade of small vessels by the pneumoperitoneum, and drying of tissues is minimal because surgery occurs in a closed environment. All of these factors contribute to reduce postoperative adhesion formation and its associated morbidity (eg, pain, impaired fertility, bowel obstruction). Today, reproductive surgery can be divided into three categories: surgery as a primary conventional surgical treatment of infertility, surgery to enhance the pregnancy outcome of in vitro fertilization, and surgery for fertility preservation [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic surgery for the treatment of female infertility is reviewed here. The evaluation and nonsurgical treatment of female infertility are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=see_link\">",
"     \"Evaluation of female infertility\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=see_link\">",
"     \"Overview of treatment of female infertility\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC LAPAROSCOPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of diagnostic laparoscopy in the management of infertility is limited. However, it can be useful in the infertility evaluation of young women with a history of pelvic inflammatory disease, ectopic pregnancy, pelvic surgery, or chronic pelvic pain. In our practice, we usually perform diagnostic laparoscopy or in vitro fertilization (IVF) treatment if three cycles of gonadotropin ovulation induction with intrauterine inseminations are unsuccessful. If adhesions or endometriosis are found during diagnostic laparoscopy and the patient has been appropriately consented, then an operative laparoscopic procedure for improving fertility can be undertaken at the same time.",
"   </p>",
"   <p>",
"    Diagnostic laparoscopy can be avoided in older women and those with multiple infertility factors. These women are better served by in vitro fertilization, instead of a surgical approach to treatment. The presence of endometriosis and adhesions does not markedly influence the effectiveness of IVF. Today, we rarely perform diagnostic laparoscopy in infertile women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=see_link\">",
"     \"In vitro fertilization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7445214\">",
"    <span class=\"h2\">",
"     Chromopertubation",
"    </span>",
"    &nbsp;&mdash;&nbsp;When laparoscopy is performed for diagnostic or therapeutic purposes in women with infertility, chromopertubation (instillation of dye through the fallopian tubes) is often performed to assess tubal patency. To perform this procedure, a dilute solution of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    dye is instilled through a transcervical cannula (typically through a patent cannula used for uterine manipulation (",
"    <a class=\"graphic graphic_picture graphicRef78608 \" href=\"UTD.htm?33/27/34239\">",
"     picture 1",
"    </a>",
"    )). Spillage of the dye from each tube is noted as a confirmation of tubal patency. If a repair procedure for tubal occlusion is performed, chromopertubation is repeated at the end of the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7445946\">",
"    <span class=\"h1\">",
"     SURGICAL ROUTE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most surgical treatments for women with infertility are performed laparoscopically. The exception to this is hysteroscopic removal of intrauterine lesions (eg, fibroid, polyp, adhesions) or hysteroscopic tubal occlusion. (See",
"    <a class=\"local\" href=\"#H4795936\">",
"     'Hysteroscopic tubal occlusion'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7445783\">",
"    <span class=\"h2\">",
"     Combined laparoscopy and hysteroscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some women who undergo diagnostic or therapeutic procedures for infertility may require both hysteroscopy and laparoscopy. As an example, a woman with ultrasound findings of an intrauterine lesion undergoing surgical treatment of endometriosis requires evaluation of the uterine cavity.",
"   </p>",
"   <p>",
"    When laparoscopic and hysteroscopic procedures are combined, the order of procedures should be based upon the indication for each procedure. If intrauterine pathology is suspected, it may be prudent to perform hysteroscopy first so that placement of the uterine cannula during laparoscopy does not cause tissue trauma that interferes with assessment of the uterine cavity. Another advantage to performing hysteroscopy followed by laparoscopy is that the peritoneal surface of the uterus can be inspected for uterine perforation that occurred during hysteroscopy. On the other hand, a potential disadvantage of performing hysteroscopy first is that tissue fragments may block the tubes and give the false impression of tubal occlusion during chromopertubation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ADHESIOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnancy can occur in women with periadnexal adhesions, but the pregnancy rate appears to be higher in those who undergo adhesiolysis. The severity of adhesions can only be evaluated at the time of surgery. For women with dense pelvic adhesions (&ldquo;frozen pelvis&rdquo;), optimal adhesiolysis is unlikely. &nbsp;",
"   </p>",
"   <p>",
"    In the only controlled study examining this issue, salpingo-ovariolysis was performed in 69 infertile women with pelvic adhesions, while 78 women with a similar degree of adhesions were not treated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/2\">",
"     2",
"    </a>",
"    ]. The cumulative pregnancy rate at 24 months follow-up was significantly higher in treated women, 45 versus 16 percent in the untreated group. Although adhesiolysis was done at laparotomy, equivalent results can be expected with laparoscopic adhesiolysis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=see_link\">",
"     \"Preventing postoperative peritoneal adhesions\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p>",
"    Intrauterine adhesions are another cause of infertility. Surgical treatment is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=see_link\">",
"     \"Intrauterine adhesions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     ENDOMETRIOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Excision and ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Whether there is an association between",
"    <span class=\"nowrap\">",
"     minimal/mild",
"    </span>",
"    endometriosis and infertility has been debated for many years. This controversy was somewhat resolved following a Canadian study in which 341 infertile women with",
"    <span class=\"nowrap\">",
"     minimal/mild",
"    </span>",
"    endometriosis were randomly assigned to undergo laparoscopic ablation or excision of endometriotic lesions or laparoscopy without further surgical intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/3\">",
"     3",
"    </a>",
"    ]. The 36-week cumulative probability of pregnancy was significantly higher in women who received surgical treatment (31 versus 18 percent in the no treatment group) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/3\">",
"     3",
"    </a>",
"    ]. In contrast, the only other randomized trial in this area did not find any difference in the pregnancy rate between the treated and no treatment groups (24 and 29 percent, respectively, at one year follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/4\">",
"     4",
"    </a>",
"    ]. These findings may have been due to the small sample size (n = 101) of the latter study as a subsequent meta-analysis of these two trials found laparoscopic surgical treatment was associated with a significant increase in the ongoing",
"    <span class=\"nowrap\">",
"     pregnancy/live",
"    </span>",
"    birth rate (OR 1.64, 95 percent CI 1.05 to 2.57) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/5\">",
"     5",
"    </a>",
"    ]. The number needed to treat (NNT) was 61; in other words, 61 patients would have to undergo laparoscopic ablation of endometriosis to achieve one pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=see_link\">",
"     \"Pathogenesis and treatment of infertility in women with endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Endometriosis can be ablated or excised laparoscopically using scissors, electrocoagulation, laser, or ultrasonic cutting and coagulation device (eg, Harmonic Scalpel&reg;) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/6\">",
"     6",
"    </a>",
"    ]. It is not known whether one modality is more effective than another. A nonrandomized study of 91 women with",
"    <span class=\"nowrap\">",
"     minimal/mild",
"    </span>",
"    endometriosis found the pregnancy rate after excision was not significantly different from than after electrocoagulation, 54 versus 57 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/7\">",
"     7",
"    </a>",
"    ]. However, in our experience, excision leads to more complete removal of endometriosis than electrocoagulation, which is especially important for women with pelvic pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Excision of endometriomas",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most effective treatment of endometriomas is excision. Medical therapy of an endometrioma larger than 1 cm is not effective [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/8-13\">",
"     8-13",
"    </a>",
"    ]; nor is aspiration, which is associated with a recurrence rate of 88 percent at six months follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Fenestration and ablation (ie, removal of part of the cyst wall followed by the coagulation of the inner side of the wall) is also less effective than excision, both in terms of improving fertility recurrence and for reducing pain [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/9,13,16-18\">",
"     9,13,16-18",
"    </a>",
"    ]. However, excision of endometrioma might be associated with decreased ovarian reserve, especially when the endometrioma cyst wall is severely adhered to the remaining ovarian tissue. In this case, the fenestration technique should be used. We usually start by attempting to perform excision. However, if the endometrioma is severely adhered to the ovarian tissue, the adhered tissue is coagulated. It seems that the presence of small endometrioma of less than 4 cm in diameter does not impair IVF outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"     \"Diagnosis and management of ovarian endometriomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT OF DISTAL TUBAL OCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal tubal obstruction is usually a sequela of salpingitis. Other causes are previous ectopic pregnancy, previous abdominal or pelvic surgery, and peritonitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5561795\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Distal tubal occlusion is usually diagnosed by hysterosalpingogram that shows dilated distal tube (hydrosalpinx). The diagnosis is established at the time of laparoscopy; chromopertubation leads to dilated distal tube with no passage of the dye.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Fimbrioplasty",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fimbrioplasty is performed for treatment of fimbrial phimosis, which is a partial obstruction of the distal end of the fallopian tube. The tube is patent, but there are adhesive bands that surround the terminal end. The longitudinal folds of the tube are usually preserved. Fimbrioplasty involves dividing the peritoneal adhesive bands that surround the fimbria. Gentle introduction of an alligator laparoscopic forceps into the tubal ostium followed by opening and withdrawal of the forceps helps to stretch the tube and release minor degrees of fimbrial agglutination [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one series of 35 infertile women with severe fimbrial occlusions treated with laparoscopic fimbrioplasty, the intrauterine pregnancy rate was 51 percent, the live birth rate was 37 percent, and the ectopic pregnancy rate was 23 percent after two years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/20\">",
"     20",
"    </a>",
"    ]. Another study found similar outcomes after fimbrioplasty or salpingostomy: the pregnancy and fecundity rates after laparoscopic fimbrioplasty were 40 and 4 percent, respectively, compared to 56 and 16 percent following salpingostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/21\">",
"     21",
"    </a>",
"    ]. The overall ectopic pregnancy rate was about 5 percent. It appears that the results of salpingostomy are equivalent to that of fimbrioplasty. The latter procedure results in more normal tubal anatomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Terminal salpingostomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Terminal salpingostomy is performed to relieve tubal obstruction associated with hydrosalpinx. Efficacy for improving fertility is generally poor, but depends upon tubal wall thickness, ampullary dilation, presence of mucosal folds, percentage of ciliated cells in the fimbrial end, and peritubal adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]. The average pregnancy rate following salpingostomy is 30 percent, with an ectopic pregnancy rate of 5 percent. However, the pregnancy rate can be as low as zero if the tube is rigid and thick without rugae, and as high as 80 percent when tubal damage is absent or minimal by hysterosalpingogram, salpingoscopy, or inspection at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery may be considered for young women with mild distal tubal disease because, if successful, one surgical procedure can lead to several pregnancies whereas IVF must be attempted each time pregnancy is desired. IVF is more likely than surgery to be successful in women with bilateral hydrosalpinx, older women (due to the rapid decline in fertility with advancing age), and women with severe disease (eg, severe hydrosalpinx, extensive and dense adhesions, both proximal and distal tubal occlusion). The pregnancy rate after reconstructive surgery in women with combined tubal occlusion (bipolar tubal blockage) is only 12 percent at 2.5 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SALPINGECTOMY BEFORE IN VITRO FERTILIZATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several reports have described a detrimental effect of hydrosalpinx on implantation and pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. The leakage of hydrosalpingeal fluid from the tube into the uterine cavity may impede implantation either by flushing the embryos out of the cavity or disrupting the endometrium at the implantation site. Furthermore, hydrosalpinx fluid contains microorganisms, debris, toxins, cytokines, and prostaglandins that may impair endometrial receptivity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/28\">",
"     28",
"    </a>",
"    ] and possibly reduce the percentage of motile spermatozoa [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On a molecular level, one group demonstrated decreased endometrial HOXA10 expression in response to hydrosalpinx fluid, with restoration of HOXA10 expression after salpingectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/30\">",
"     30",
"    </a>",
"    ]. Since HOXA10 is an important transcription factor for implantation of the embryo, impaired expression of this gene may be a mechanism for the deleterious effect of hydrosalpinges on implantation during IVF.",
"   </p>",
"   <p>",
"    The deleterious effects of hydrosalpinx on achieving pregnancy in women undergoing IVF was demonstrated by the following meta-analyses:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One meta-analysis of the clinical pregnancy rate in 5569 IVF cycles without hydrosalpinx and 1144 cycles with hydrosalpinx found this rate was about 50 percent lower and the miscarriage rate more than twofold higher in patients with hydrosalpinx [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/31\">",
"       31",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another meta-analysis in which all of the women had tubal factor infertility reported the pregnancy rate in women with hydrosalpinx was lower than in women without hydrosalpinx, 20 versus 31 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/32\">",
"       32",
"      </a>",
"      ]. The incidence of early pregnancy loss was also higher in the hydrosalpinx group 44 versus 31 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Pregnancy rates can be improved by removal of unilateral or bilateral hydrosalpinges prior to IVF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A trial that randomly assigned women with hydrosalpinges to salpingectomy or no salpingectomy before their IVF procedure reported implantation and pregnancy rates per transfer in the salpingectomy group were 10 and 34 percent, respectively, but were only 5 and 19 percent in those without salpingectomy [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of five randomized trials including 646 women confirmed an increase in the rate of ongoing pregnancy in women with hydrosalpinges who were treated prior to IVF with laparoscopic salpingectomy (odds ratio [OR] 2.14, 95% CI 1.23-3.73) compared with no treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/34\">",
"       34",
"      </a>",
"      ]. Trials of laparoscopic tubal occlusion versus no treatment had insufficient power to detect a significant difference in the rate of ongoing pregnancy (OR 7.24, 95% CI 0.87-59.57), but did find a significant increase in the rate of clinical pregnancy (OR 4.66, 95% CI 2.47-10.01). Throughout the different comparisons, no significant differences were seen in adverse effects of surgical treatments. A nonsurgical approach, ultrasound guided aspiration of hydrosalpinges did not have a significant increase in the rate of clinical pregnancy (OR 1.97, 95% CI 0.62 to 6.29).",
"     </li>",
"     <li>",
"      A prospective study reported that the relative increase in the pregnancy rate after salpingectomy was greatest in women with a large hydrosalpinx visible on ultrasound (hazard ratio 3.8, 95% CI 1.5-9.2) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Salpingostomy can eliminate the accumulation of hydrosalpinx fluid without removing the tube. The tube becomes patent and the fluid will not reaccumulate because drainage is maintained. In one small study, pregnancy rates were similar to those after salpingectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/36\">",
"     36",
"    </a>",
"    ]. Further research is required to determine whether laparoscopic salpingostomy is as effective as salpingectomy. In addition, reocclusion may occur.",
"   </p>",
"   <p>",
"    Drainage of the hydrosalpinx at the time of oocyte collection is not effective as the tubes will refill rapidly (as little as two days) and the primary pathology (blocked tube) remains [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of antibiotics to treat hydrosalpinx prior to IVF has also been advocated. In one study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    was administered to women with documented hydrosalpinx before and after oocyte retrieval [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/38\">",
"     38",
"    </a>",
"    ]. In patients with tubal occlusion or obstruction, endometriosis, and unexplained infertility who received the antibiotic, the implantation rates were 30, 27, and 24 percent, respectively. The authors concluded that antibiotic administration in patients with hydrosalpinx achieved IVF success rates similar to those in controls, and was less costly than surgery.",
"   </p>",
"   <p>",
"    A small randomized trial reported that proximal tubal occlusion using bipolar diathermy prior to IVF also improved implantation and pregnancy rates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/39\">",
"     39",
"    </a>",
"    ]. Proximal tubal occlusion was not more effective than salpingectomy. We perform laparoscopic tubal occlusion if the distal tube is completely buried in dense adhesions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4795936\">",
"    <span class=\"h2\">",
"     Hysteroscopic tubal occlusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;To prevent the hydrosalpinx fluid from entering the uterine cavity, hysteroscopic tubal occlusion using procedures intended for hysteroscopic sterilization has been proposed. Some data suggest that insertion of the Essure&reg; micro-insert increases the pregnancy and live birth rates in a small number of women with hydrosalpinx treated with IVF [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/40-42\">",
"     40-42",
"    </a>",
"    ]. In our practice, we have used this approach only for women who are poor candidates for laparoscopy. Further study of this approach is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopic salpingectomy for hydrosalpinges (unilateral or bilateral) is the preferred procedure for improving pregnancy rates from IVF. Alternatives such as salpingostomy, antibiotic therapy, and proximal tubal occlusion were effective in small studies, but there are insufficient data to recommend them as a first line therapeutic intervention.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     TREATMENT OF PROXIMAL TUBAL OCCLUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of true cornual occlusion is low and surgical treatment (ie, resection and anastomosis) is not highly successful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hysterosalpingographic findings suggestive of cornual or proximal tubal occlusion must be interpreted with caution as sensitivity and specificity are only 65 and 83 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/43\">",
"     43",
"    </a>",
"    ]. In one study of resected tubes thought to be proximally occluded by hysterosalpingography",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    laparoscopy but later found to have normal histology, the etiologies of the false positive diagnosis were presumed to be amorphous debris or minimal adhesions (40 percent), extensive fibrosis or salpingitis isthmica nodosa (about 40 percent), and tubal spasm (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/44\">",
"     44",
"    </a>",
"    ]. In addition, we reported that repeat hysterosalpingogram in 98 women with hysterosalpingographic findings of bilateral proximal tubal occlusion revealed bilateral tubal patency in 14 women and patency of one of the tubes in 12 others; true occlusion was encountered in 72 patients (74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the fallopian tubes are not visualized on hysterosalpingogram, a repeat procedure should be done to exclude the possibility of a random technical problem or tubal spasm. If the test remains abnormal, then selective tubal catheterization under fluoroscopic or hysteroscopic control is indicated to confirm the diagnosis and potentially open the tube (see below) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Nonsurgical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective tubal catheterization alone is successful in obtaining tubal patency in 60 to 80 percent of patients, with pregnancy rates of 20 to 60 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]; however, most studies did not have a control group of nontreated patients. Approximately one-half of the pregnancies occur in the first 12 months after the procedure. Women with good tubal perfusion pressures had significantly higher pregnancy rates than those with medium or poor perfusion pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Tubocornual anastomosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubocornual anastomosis can be performed in women with true cornual obstruction. The cornual portion of the tube is resected followed by anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/51\">",
"     51",
"    </a>",
"    ]. Depending upon the extent and severity of tubal damage, intrauterine pregnancy rates range from 16 to 55 percent and ectopic pregnancy rates are 7 to 30 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/22\">",
"     22",
"    </a>",
"    ]. Since this procedure is traditionally performed by laparotomy, rather than laparoscopically, and the intrauterine pregnancy rate is relatively low, IVF is often a better alternative. Tubocornual anastomosis can be performed by laparoscopy; however, the number of reported cases is small [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Selective tubal catheterization may achieve tubal patency and improve short-term pregnancy rates in women who appear to have proximal tubal occlusion by hysterosalpingography. In women with true cornual occlusion, IVF is likely to be more successful than tubocornual anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TUBAL REANASTOMOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Indications for tubal anastomosis include reversal of sterilization, midtubal block secondary to pathology, tubal occlusion from ectopic pregnancy, and salpingitis isthmica nodosa. The goal is to remove abnormal tissue and reapproximate the healthy tubal segments with as little adhesion formation as possible. The technique involves microsuturing using 6-0 to 10-0 sutures.",
"   </p>",
"   <p>",
"    Sterilization reversal, although not always successful, is the most successful surgical reconstructive procedure for improving fertility. Factors that may influence the success rate of tubal reanastomosis include the age of the patient, time from sterilization, and sterilization technique. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=see_link\">",
"     \"Surgical sterilization of women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In one large series, pregnancy rates after sterilization reversal among women aged 15 to 30 years, 30 to 33 years, and 34 to 49 years were 73, 64, and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/53\">",
"     53",
"    </a>",
"    ]. Most pregnancies occurred within two years after reversal. Of interest, 23 percent of patients subsequently underwent another sterilization. In another series, tubal anastomosis resulted in live births in 41 percent of women with a previous electrocautery procedure, 50 percent of those who had a Pomeroy tubal ligation, 75 percent of women with rings, and 84 percent of those with clips [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a retrospective cohort study of 163 patients, the cumulative delivery rate over 72 months was comparable in women who had undergone IVF versus those who had surgical sterilization reversal (52 versus 60 percent). The only significant difference in delivery rates was found in a subset of patients aged &lt;37 years (52 percent after IVF and 72 percent after reversal). Surgery is associated with lower cost than IVF. Based on their findings, we could consider laparoscopic sterilization reversal in women younger than 37 years who have &ge;4 cm of residual tube. For others, IVF is a better option [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indeed, tubal length is another important factor in successful reversal. The pregnancy rate after tubal anastomosis is 75 percent in women with tubal length of 4 cm or more, but only 19 percent in those with shorter tubes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pregnancy rates after laparoscopic tubal anastomosis and conventional microsurgical anastomosis are equivalent, 80 to 81 percent 12 months after surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/57\">",
"     57",
"    </a>",
"    ]. Ectopic pregnancy rates are also similar at 2.5 to 2.8 percent. However, the laparoscopic approach is more economical: at our institution $861 for laparoscopic reconstruction versus $1348 with laparotomy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/58\">",
"     58",
"    </a>",
"    ]. The disadvantage of laparoscopic tubal anastomosis is that it is more demanding technically than an open microsurgical procedure.",
"   </p>",
"   <p>",
"    Tubal reanastomosis can also be performed using robot-assisted laparoscopy. In preliminary studies, tubal reanastomosis using robot-assisted laparoscopy compared with conventional laparoscopy and minilaparotomy appears to have a similar success rate and a short recovery time, but longer operative times and higher costs [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. Comparisons of conventional laparoscopy with minilaparotomy have found that the laparoscopic approach is effective and cost-efficient, but is technically demanding. Further study is needed to evaluate whether robotics facilitate a minimally invasive approach. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Tubal reanastomosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are few comparative studies of robotic tubal reanastomosis. Existing studies are limited by a lack of data regarding the surgeon's level of experience with robotics, which may impact operative time.",
"   </p>",
"   <p>",
"    Observational studies have compared robotic-assisted laparoscopy with minilaparotomy tubal reanastomosis and found that the two procedures were associated with similar intrauterine pregnancy rates at 9- to 10-month follow-up (27 to 74 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]; there was no consistent effect on the rate of ectopic pregnancy. Robotic procedures had significantly longer operative times (3.4 to 3.8 versus 2.6 to 3.0 hours); no differences in complication rates were reported. Women in the robotic group had a faster return to normal activities (11 versus 20 to 28 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We consider sterilization reversal in young women with more than 4 cm of residual tube and prior ring or clip sterilization. In other women, IVF may be a better option. We recommend a laparoscopic approach (for the usual advantages of laparoscopic surgery) if a surgeon experienced in laparoscopic tubal anastomosis is available. Otherwise, laparotomy can be performed with good results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     OVARIAN WEDGE RESECTION AND DRILLING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first line of treatment for polycystic ovary syndrome (PCOS)-related anovulatory infertility is change in lifestyle and medical treatment, using drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"     clomiphene",
"    </a>",
"    citrate, gonadotropins, gonadotropin-releasing hormone, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"     metformin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=see_link\">",
"     \"Treatment of polycystic ovary syndrome in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=see_link\">",
"     \"Metformin for treatment of the polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The traditional surgical treatment for PCOS was ovarian wedge resection. The procedure was performed by excising approximately one third of the ovary via laparotomy. In an initial series of 108 patients undergoing bilateral ovarian wedge resection, regular menstrual cyclicity was restored in 95 percent of patients, with a pregnancy rate of 85 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/64\">",
"     64",
"    </a>",
"    ]. Subsequent reports confirmed the benefits of the procedure, with varying rates of success. However, it became clear that wedge resection was often associated with development of periadnexal adhesions, thus obviating the beneficial effects of surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/63\">",
"     63",
"    </a>",
"    ]. Ovarian wedge resection can also be performed laparoscopically [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. One small series of 25 patients reported a pregnancy rate of 60 percent; however, 36 percent of patients developed postoperative adhesions, again negating some of the benefits of the surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, ovarian resection, whether performed laparoscopically or by laparotomy, is associated with substantial tissue loss. Instances of premature ovarian failure have been described, rendering the procedure obsolete by any approach [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laparoscopic ovarian drilling is a modification of the ovarian wedge resection. Multiple holes are made on the surface of the ovary using either laser or electrocautery. This results in a decrease in circulating androgen levels, with resumption of cyclic ovulation. The procedure is associated with an ovulation rate of 80 percent and pregnancy rates at 12, 18, and 24 months of 54 to 68, 62 to 73, and 68 to 82 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/68-70\">",
"     68-70",
"    </a>",
"    ]. Although these results are encouraging, long-term effects are not known. Therefore, a surgical approach to treatment of PCOS is recommended only in those women who meet the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure of ovulation despite an adequate trial of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/22/23909?source=see_link\">",
"       clomiphene",
"      </a>",
"      citrate and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?7/48/7944?source=see_link\">",
"       metformin",
"      </a>",
"     </li>",
"     <li>",
"      Normal weight, because the procedure is often unsuccessful in obese women (body mass index &gt;30",
"      <span class=\"nowrap\">",
"       kg/m2",
"      </span>",
"      body surface area)",
"     </li>",
"     <li>",
"      Absence of other causes of infertility",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A detailed discussion of laparoscopic ovarian drilling for treatment of PCOS can be found separately. With the availability of in vitro fertilization and in vitro maturation treatments, we rarely perform this procedure any more. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=see_link\">",
"     \"Laparoscopic surgery for ovulation induction in polycystic ovary syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     LEIOMYOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of leiomyoma to enhance fertility in subfertile women is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=see_link\">",
"     \"Reproductive issues in women with uterine leiomyomas (fibroids)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LAPAROSCOPIC PRESERVATION OF FERTILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;We perform laparoscopic surgery for preservation of ovarian function and fertility in young women at risk of premature ovarian failure, such as those undergoing chemotherapy or radiation therapy for malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/18/9513/abstract/71\">",
"     71",
"    </a>",
"    ]. Options for these women are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=see_link\">",
"     \"Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The role of diagnostic laparoscopy in the management of infertility is limited. However, it can be useful in the infertility evaluation of young women with a history of pelvic inflammatory disease, ectopic pregnancy, pelvic surgery, or chronic pelvic pain. If adhesions or endometriosis are found during diagnostic laparoscopy, then an operative laparoscopic procedure for improving fertility can be undertaken at the same time. If successful, one surgical procedure can lead to several pregnancies whereas in vitro fertilization (IVF) must be attempted each time pregnancy is desired. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnostic laparoscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Endometriosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of distal tubal occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnostic laparoscopy can be avoided in older women and those with multiple infertility factors. These women are better served by IVF, instead of a surgical approach to treatment, because IVF is more likely than surgery to be successful in women with bilateral hydrosalpinx, older women (due to the rapid decline in fertility with advancing age), and women with severe disease (eg, severe hydrosalpinx, extensive and dense adhesions, both proximal and distal tubal occlusion). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Diagnostic laparoscopy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Endometriosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment of distal tubal occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laparoscopic salpingectomy for hydrosalpinges is the preferred procedure for improving pregnancy rates in women planning to undergo IVF. Alternatives such as proximal tubal occlusion, salpingostomy and antibiotic therapy have been shown to be effective in small studies, but there are insufficient data to recommend them as a first line therapeutic intervention. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Salpingectomy before in vitro fertilization'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest selective tubal catheterization in women who appear to have proximal tubal occlusion by hysterosalpingography. In women with true cornual occlusion, IVF is more likely to be effective than tubocornual anastomosis. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Treatment of proximal tubal occlusion'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest sterilization reversal in young women with more than 4 cm of residual tube. In other women, IVF appears to be a better option. We recommend a laparoscopic approach (for the usual advantages of laparoscopic surgery) if a surgeon experienced in laparoscopic tubal anastomosis is available. Otherwise, laparotomy can be performed with good results. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Tubal reanastomosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/1\">",
"      Tulandi T, Marzal A. Redefining reproductive surgery. J Minim Invasive Gynecol 2012; 19:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/2\">",
"      Tulandi T, Collins JA, Burrows E, et al. Treatment-dependent and treatment-independent pregnancy among women with periadnexal adhesions. Am J Obstet Gynecol 1990; 162:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/3\">",
"      Marcoux S, Maheux R, B&eacute;rub&eacute; S. Laparoscopic surgery in infertile women with minimal or mild endometriosis. Canadian Collaborative Group on Endometriosis. N Engl J Med 1997; 337:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/4\">",
"      Parazzini F. Ablation of lesions or no treatment in minimal-mild endometriosis in infertile women: a randomized trial. Gruppo Italiano per lo Studio dell'Endometriosi. Hum Reprod 1999; 14:1332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/5\">",
"      Jacobson TZ, Barlow DH, Koninckx PR, et al. Laparoscopic surgery for subfertility associated with endometriosis. Cochrane Database Syst Rev 2002; :CD001398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/6\">",
"      Garner, E. Laparoscopy in the management of endometriosis. Infertil Reprod Med Clinics North Am 1997; 8:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/7\">",
"      Tulandi T, al-Took S. Reproductive outcome after treatment of mild endometriosis with laparoscopic excision and electrocoagulation. Fertil Steril 1998; 69:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/8\">",
"      Bateman BG, Kolp LA, Mills S. Endoscopic versus laparotomy management of endometriomas. Fertil Steril 1994; 62:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/9\">",
"      Saleh A, Tulandi T. Reoperation after laparoscopic treatment of ovarian endometriomas by excision and by fenestration. Fertil Steril 1999; 72:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/10\">",
"      Hemmings R, Bissonnette F, Bouzayen R. Results of laparoscopic treatments of ovarian endometriomas: laparoscopic ovarian fenestration and coagulation. Fertil Steril 1998; 70:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/11\">",
"      Loh FH, Tan AT, Kumar J, Ng SC. Ovarian response after laparoscopic ovarian cystectomy for endometriotic cysts in 132 monitored cycles. Fertil Steril 1999; 72:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/12\">",
"      Donnez J, Wyns C, Nisolle M. Does ovarian surgery for endometriomas impair the ovarian response to gonadotropin? Fertil Steril 2001; 76:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/13\">",
"      Beretta P, Franchi M, Ghezzi F, et al. Randomized clinical trial of two laparoscopic treatments of endometriomas: cystectomy versus drainage and coagulation. Fertil Steril 1998; 70:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/14\">",
"      Vercellini P, Vendola N, Bocciolone L, et al. Laparoscopic aspiration of ovarian endometriomas. Effect with postoperative gonadotropin releasing hormone agonist treatment. J Reprod Med 1992; 37:577.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/15\">",
"      Saleh, A, Tulandi, T. Surgical management of ovarian endometrioma. Infertil Reprod Med Clin North Am 2000; 11:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/16\">",
"      Vercellini P, Chapron C, De Giorgi O, et al. Coagulation or excision of ovarian endometriomas? Am J Obstet Gynecol 2003; 188:606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/17\">",
"      Jones KD, Sutton C. Patient satisfaction and changes in pain scores after ablative laparoscopic surgery for stage III-IV endometriosis and endometriotic cysts. Fertil Steril 2003; 79:1086.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/18\">",
"      Alborzi S, Momtahan M, Parsanezhad ME, et al. A prospective, randomized study comparing laparoscopic ovarian cystectomy versus fenestration and coagulation in patients with endometriomas. Fertil Steril 2004; 82:1633.",
"     </a>",
"    </li>",
"    <li>",
"     Namnoum A, Murphy A. Diagnostic and Operative Laparoscopy. In: TeLinde's Operative Gynecology, 8th ed, Lippincott-Raven, Philadelphia 1997. p.389.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/20\">",
"      Audebert AJ, Pouly JL, Von Theobald P. Laparoscopic fimbrioplasty: an evaluation of 35 cases. Hum Reprod 1998; 13:1496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/21\">",
"      Saleh WA, Dlugi AM. Pregnancy outcome after laparoscopic fimbrioplasty in nonocclusive distal tubal disease. Fertil Steril 1997; 67:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/22\">",
"      Hesla, J. Laparoscopic management of distal tubal disease. Infertil Reprod Med Clinics North Am 1997; 8:3:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/23\">",
"      Marana R, Catalano GF, Muzii L, et al. The prognostic role of salpingoscopy in laparoscopic tubal surgery. Hum Reprod 1999; 14:2991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/24\">",
"      Schlaff WD, Hassiakos DK, Damewood MD, Rock JA. Neosalpingostomy for distal tubal obstruction: prognostic factors and impact of surgical technique. Fertil Steril 1990; 54:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/25\">",
"      Rock JA, Katayama KP, Martin EJ, et al. Factors influencing the success of salpingostomy techniques for distal fimbrial obstruction. Obstet Gynecol 1978; 52:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/26\">",
"      Patton PE, Williams TJ, Coulam CB. Results of microsurgical reconstruction in patients with combined proximal and distal tubal occlusion: double obstruction. Fertil Steril 1987; 48:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/27\">",
"      Strandell A, Lindhard A. Why does hydrosalpinx reduce fertility? The importance of hydrosalpinx fluid. Hum Reprod 2002; 17:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/28\">",
"      Meyer WR, Castelbaum AJ, Somkuti S, et al. Hydrosalpinges adversely affect markers of endometrial receptivity. Hum Reprod 1997; 12:1393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/29\">",
"      Ng EH, Ajonuma LC, Lau EY, et al. Adverse effects of hydrosalpinx fluid on sperm motility and survival. Hum Reprod 2000; 15:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/30\">",
"      Daftary GS, Kayisli U, Seli E, et al. Salpingectomy increases peri-implantation endometrial HOXA10 expression in women with hydrosalpinx. Fertil Steril 2007; 87:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/31\">",
"      Zeyneloglu HB, Arici A, Olive DL. Adverse effects of hydrosalpinx on pregnancy rates after in vitro fertilization-embryo transfer. Fertil Steril 1998; 70:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/32\">",
"      Camus E, Poncelet C, Aucouturier JS, et al. [Hydrosalpinx and fertilization in vitro-embryo transfer: abstention or salpingectomy? Abstention, salpingectomy or salpingostomy?]. Gynecol Obstet Fertil 2001; 29:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/33\">",
"      Dechaud H. Hydrosalpinx and ART: hydrosalpinges suitable for salpingectomy before IVF. Hum Reprod 2000; 15:2464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/34\">",
"      Johnson N, van Voorst S, Sowter MC, et al. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation. Cochrane Database Syst Rev 2010; :CD002125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/35\">",
"      Bildirici I, Bukulmez O, Ensari A, et al. A prospective evaluation of the effect of salpingectomy on endometrial receptivity in cases of women with communicating hydrosalpinges. Hum Reprod 2001; 16:2422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/36\">",
"      Murray DL, Sagoskin AW, Widra EA, Levy MJ. The adverse effect of hydrosalpinges on in vitro fertilization pregnancy rates and the benefit of surgical correction. Fertil Steril 1998; 69:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/37\">",
"      Bloechle M, Schreiner T, Lisse K. Recurrence of hydrosalpinges after transvaginal aspiration of tubal fluid in an IVF cycle with development of a serometra. Hum Reprod 1997; 12:703.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/38\">",
"      Hurst BS, Tucker KE, Awoniyi CA, Schlaff WD. Hydrosalpinx treated with extended doxycycline does not compromise the success of in vitro fertilization. Fertil Steril 2001; 75:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/39\">",
"      Kontoravdis A, Makrakis E, Pantos K, et al. Proximal tubal occlusion and salpingectomy result in similar improvement in in vitro fertilization outcome in patients with hydrosalpinx. Fertil Steril 2006; 86:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/40\">",
"      Hitkari JA, Singh SS, Shapiro HM, Leyland N. Essure treatment of hydrosalpinges. Fertil Steril 2007; 88:1663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/41\">",
"      Mijatovic V, Veersema S, Emanuel MH, et al. Essure hysteroscopic tubal occlusion device for the treatment of hydrosalpinx prior to in vitro fertilization-embryo transfer in patients with a contraindication for laparoscopy. Fertil Steril 2010; 93:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/42\">",
"      Galen DI, Khan N, Richter KS. Essure multicenter off-label treatment for hydrosalpinx before in vitro fertilization. J Minim Invasive Gynecol 2011; 18:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/43\">",
"      Mol BW, Swart P, Bossuyt PM, van der Veen F. Is hysterosalpingography an important tool in predicting fertility outcome? Fertil Steril 1997; 67:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/44\">",
"      Sulak PJ, Letterie GS, Coddington CC, et al. Histology of proximal tubal occlusion. Fertil Steril 1987; 48:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/45\">",
"      Al-Jaroudi D, Herba MJ, Tulandi T. Reproductive performance after selective tubal catheterization. J Minim Invasive Gynecol 2005; 12:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/46\">",
"      Woolcott R, Fisher S, Thomas J, Kable W. A randomized, prospective, controlled study of laparoscopic dye studies and selective salpingography as diagnostic tests of fallopian tube patency. Fertil Steril 1999; 72:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/47\">",
"      Papaioannou S, Afnan M, Girling AJ, et al. Long-term fertility prognosis following selective salpingography and tubal catheterization in women with proximal tubal blockage. Hum Reprod 2002; 17:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/48\">",
"      Sankpal RS, Confino E, Matzel A, Cohen LS. Investigation of the uterine cavity and fallopian tubes using three-dimensional saline sonohysterosalpingography. Int J Gynaecol Obstet 2001; 73:125.",
"     </a>",
"    </li>",
"    <li>",
"     Mishell D, Stenchever M, Droegemueller W, Herbst A. Infertility, etiology, diagnostic evaluation, management and diagnosis. In: Comprehensive Gynecology, 3rd ed, Mosby-Year Book, Inc., St. Louis, 1997, p. 1113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/50\">",
"      Papaioannou S, Afnan M, Girling AJ, et al. The effect on pregnancy rates of tubal perfusion pressure reductions achieved by guide-wire tubal catheterization. Hum Reprod 2002; 17:2174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/51\">",
"      Spielvogel K, Shwayder J, Coddington CC. Surgical management of adhesions, endometriosis, and tubal pathology in the woman with infertility. Clin Obstet Gynecol 2000; 43:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/52\">",
"      Gomel V, McComb PF. Microsurgery for tubal infertility. J Reprod Med 2006; 51:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/53\">",
"      Trussell J, Guilbert E, Hedley A. Sterilization failure, sterilization reversal, and pregnancy after sterilization reversal in Quebec. Obstet Gynecol 2003; 101:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/54\">",
"      Yoon TK, Sung HR, Cha SH, et al. Fertility outcome after laparoscopic microsurgical tubal anastomosis. Fertil Steril 1997; 67:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/55\">",
"      Boeckxstaens A, Devroey P, Collins J, Tournaye H. Getting pregnant after tubal sterilization: surgical reversal or IVF? Hum Reprod 2007; 22:2660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/56\">",
"      Rock JA, Guzick DS, Katz E, et al. Tubal anastomosis: pregnancy success following reversal of Falope ring or monopolar cautery sterilization. Fertil Steril 1987; 48:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/57\">",
"      Cha SH, Lee MH, Kim JH, et al. Fertility outcome after tubal anastomosis by laparoscopy and laparotomy. J Am Assoc Gynecol Laparosc 2001; 8:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/58\">",
"      Hawkins J, Dube D, Kaplow M, Tulandi T. Cost analysis of tubal anastomosis by laparoscopy and by laparotomy. J Am Assoc Gynecol Laparosc 2002; 9:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/59\">",
"      Goldberg JM, Falcone T. Laparoscopic microsurgical tubal anastomosis with and without robotic assistance. Hum Reprod 2003; 18:145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/60\">",
"      Rodgers AK, Goldberg JM, Hammel JP, Falcone T. Tubal anastomosis by robotic compared with outpatient minilaparotomy. Obstet Gynecol 2007; 109:1375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/61\">",
"      Dharia Patel SP, Steinkampf MP, Whitten SJ, Malizia BA. Robotic tubal anastomosis: surgical technique and cost effectiveness. Fertil Steril 2008; 90:1175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/62\">",
"      Garcia J, Jones GS, Wentz AC. The use of clomiphene citrate. Fertil Steril 1977; 28:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/63\">",
"      Pirwany I, Tulandi T. Laparoscopic treatment of polycystic ovaries: is it time to relinquish the procedure? Fertil Steril 2003; 80:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/64\">",
"      STEIN IF Sr. DURATION OF FERTILITY FOLLOWING OVARIAN WEDGE RESECTION--STEIN-LEVENTHAL SYNDROME. West J Surg Obstet Gynecol 1964; 72:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/65\">",
"      McLaughlin DS. Evaluation of adhesion reformation by early second-look laparoscopy following microlaser ovarian wedge resection. Fertil Steril 1984; 42:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/66\">",
"      Yanagibori A, Kojima E, Ohtaka K, et al. Nd:YAG laser therapy for infertility with a contact-type probe. J Reprod Med 1989; 34:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/67\">",
"      Toaff R, Toaff ME, Peyser MR. Infertility following wedge resection of the ovaries. Am J Obstet Gynecol 1976; 124:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/68\">",
"      Heylen SM, Puttemans PJ, Brosens IA. Polycystic ovarian disease treated by laparoscopic argon laser capsule drilling: comparison of vaporization versus perforation technique. Hum Reprod 1994; 9:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/69\">",
"      Li TC, Saravelos H, Chow MS, et al. Factors affecting the outcome of laparoscopic ovarian drilling for polycystic ovarian syndrome in women with anovulatory infertility. Br J Obstet Gynaecol 1998; 105:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/70\">",
"      Felemban A, Tan SL, Tulandi T. Laparoscopic treatment of polycystic ovaries with insulated needle cautery: a reappraisal. Fertil Steril 2000; 73:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/18/9513/abstract/71\">",
"      Tulandi T, Huang JY, Tan SL. Preservation of female fertility: an essential progress. Obstet Gynecol 2008; 112:1160.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3279 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9513=[""].join("\n");
var outline_f9_18_9513=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DIAGNOSTIC LAPAROSCOPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7445214\">",
"      Chromopertubation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7445946\">",
"      SURGICAL ROUTE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7445783\">",
"      Combined laparoscopy and hysteroscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ADHESIOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      ENDOMETRIOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Excision and ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Excision of endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT OF DISTAL TUBAL OCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5561795\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Fimbrioplasty",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Terminal salpingostomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SALPINGECTOMY BEFORE IN VITRO FERTILIZATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4795936\">",
"      Hysteroscopic tubal occlusion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      TREATMENT OF PROXIMAL TUBAL OCCLUSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Nonsurgical therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Tubocornual anastomosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TUBAL REANASTOMOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      OVARIAN WEDGE RESECTION AND DRILLING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      LEIOMYOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LAPAROSCOPIC PRESERVATION OF FERTILITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/3279\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/3279|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/27/34239\" title=\"picture 1\">",
"      Cohen cannula",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/61/40921?source=related_link\">",
"      Evaluation of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/7/38010?source=related_link\">",
"      Fertility preservation in patients undergoing gonadotoxic treatment or gonadal resection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/56/37770?source=related_link\">",
"      In vitro fertilization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26101?source=related_link\">",
"      Intrauterine adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/0/24583?source=related_link\">",
"      Laparoscopic surgery for ovulation induction in polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/27/16826?source=related_link\">",
"      Metformin for treatment of the polycystic ovary syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/5/14425?source=related_link\">",
"      Overview of treatment of female infertility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/15/38136?source=related_link\">",
"      Pathogenesis and treatment of infertility in women with endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/47/26359?source=related_link\">",
"      Preventing postoperative peritoneal adhesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/60/30662?source=related_link\">",
"      Reproductive issues in women with uterine leiomyomas (fibroids)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/42/15018?source=related_link\">",
"      Surgical sterilization of women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/49/1817?source=related_link\">",
"      Treatment of polycystic ovary syndrome in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_18_9514="Verapamil: Drug information";
var content_f9_18_9514=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Verapamil: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?5/53/5974?source=see_link\">",
"    see \"Verapamil: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"    see \"Verapamil: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F233861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Calan&reg;;",
"     </li>",
"     <li>",
"      Calan&reg; SR;",
"     </li>",
"     <li>",
"      Covera-HS&reg; [DSC];",
"     </li>",
"     <li>",
"      Isoptin&reg; SR;",
"     </li>",
"     <li>",
"      Verelan&reg;;",
"     </li>",
"     <li>",
"      Verelan&reg; PM",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F233862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Verap&reg;;",
"     </li>",
"     <li>",
"      Apo-Verap&reg; SR;",
"     </li>",
"     <li>",
"      Covera-HS&reg;;",
"     </li>",
"     <li>",
"      Covera&reg;;",
"     </li>",
"     <li>",
"      Dom-Verapamil SR;",
"     </li>",
"     <li>",
"      Isoptin&reg; SR;",
"     </li>",
"     <li>",
"      Mylan-Verapamil;",
"     </li>",
"     <li>",
"      Mylan-Verapamil SR;",
"     </li>",
"     <li>",
"      Novo-Veramil;",
"     </li>",
"     <li>",
"      Novo-Veramil SR;",
"     </li>",
"     <li>",
"      Nu-Verap;",
"     </li>",
"     <li>",
"      Nu-Verap SR;",
"     </li>",
"     <li>",
"      PHL-Verapamil SR;",
"     </li>",
"     <li>",
"      PMS-Verapamil SR;",
"     </li>",
"     <li>",
"      PRO-Verapamil SR;",
"     </li>",
"     <li>",
"      Riva-Verapamil SR;",
"     </li>",
"     <li>",
"      Verapamil Hydrochloride Injection, USP;",
"     </li>",
"     <li>",
"      Verapamil SR;",
"     </li>",
"     <li>",
"      Verelan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F233911\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antianginal Agent;",
"     </li>",
"     <li>",
"      Antiarrhythmic Agent, Class IV;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker;",
"     </li>",
"     <li>",
"      Calcium Channel Blocker, Nondihydropyridine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F233866\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Angina:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     When switching from immediate-release to extended/sustained release formulations, the total daily dose remains the same unless formulation strength does not allow for equal conversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     Initial: 80-120 mg 3 times/day (elderly or small stature: 40 mg 3 times/day); Usual dose  range (Gibbons, 2003): 80-160 mg 3 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release",
"     </i>",
"     (Covera-HS&reg;): Initial: 180 mg once daily at bedtime; if inadequate response, may increase dose at weekly intervals to 240 mg once daily, then 360 mg once daily, then 480 mg once daily; maximum dose: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chronic atrial fibrillation (rate-control), PSVT prophylaxis:",
"     </b>",
"     Oral: Immediate release: 240-480 mg/day in 3-4 divided doses; Usual dose range (Fuster, 2006): 120-360 mg/day in divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     When switching from immediate-release to extended/sustained release formulations, the total daily dose remains the same unless formulation strength does not allow for equal conversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Immediate release:",
"     </i>",
"     80 mg 3 times/day; usual dose range (JNC 7): 80-320 mg/day in 2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Sustained release:",
"     </i>",
"     Usual dose range (JNC 7): 120-480 mg/day in 1-2 divided doses;",
"     <b>",
"      Note:",
"     </b>",
"     There is no evidence of additional benefit with doses &gt;360 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Calan&reg; SR, Isoptin&reg; SR: Initial: 180 mg once daily in the morning (elderly or small stature: 120 mg/day); if inadequate response, may increase dose at weekly intervals to 240 mg once daily, then 180 mg twice daily (or 240 mg in the morning followed by 120 mg in the evening); maximum dose: 240 mg twice daily.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Verelan&reg;: Initial: 180 mg once daily in the morning (elderly or small stature: 120 mg/day); if inadequate response, may increase dose at weekly intervals to 240 mg once daily, then 360 mg once daily, then 480 mg once daily; maximum dose: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Extended release:",
"     </i>",
"     Usual dose range (JNC 7): 120-360 mg once daily (once-daily dosing is recommended at bedtime)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Covera-HS&reg;: Initial: 180 mg once daily at bedtime; if inadequate response, may increase dose at weekly intervals to 240 mg once daily, then 360 mg once daily, then 480 mg once daily; maximum dose: 480 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Verelan&reg; PM: Initial: 200 mg once daily at bedtime (elderly or small stature: 100 mg/day); if inadequate response, may increase dose at weekly intervals to 300 mg once daily, then 400 mg once daily; maximum dose: 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      SVT (ACLS, 2010):",
"     </b>",
"     I.V.: 2.5-5 mg over 2 minutes; second dose of 5-10 mg (~0.15 mg/kg) may be given 15-30 minutes after the initial dose if patient tolerates, but does not respond to initial dose; maximum total dose: 20-30 mg",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9729804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=see_link\">",
"      see \"Verapamil: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      SVT:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     Verapamil is no longer included in the Pediatric Advanced Life Support (PALS) tachyarrhythmia algorithm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children: 1-15 years: I.V.: 0.1-0.3 mg/kg/dose over 2 minutes; maximum: 5 mg/dose, may repeat dose in 30 minutes if inadequate response; maximum for second dose: 10 mg",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F233867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Hypertension:",
"     </b>",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     When switching from immediate release to extended or sustained release formulations, the total daily dose remains the same unless formulation strength does not allow for equal conversion.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Manufacturer&rsquo;s recommendations:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Immediate release: Initial: 40 mg 3 times daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Sustained release: Calan&reg; SR, Isoptin&reg; SR,Verelan&reg;: Initial: 120 mg once daily in the morning",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;margin-top:0em;text-align:justify;\">",
"     Extended release:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Covera-HS&reg;: Initial: 180 mg once daily at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;margin-top:0em;text-align:justify;\">",
"     Verelan&reg; PM: Initial: 100 mg once daily at bedtime",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     ACCF/AHA Expert Consensus recommendations: Consider lower initial doses and titrating to response (Aronow, 2011)",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F233868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Manufacturer recommends caution and additional ECG monitoring in patients with renal insufficiency. The manufacturer of Verelan PM&reg; recommends an initial dose of 100 mg/day at bedtime.",
"     <b>",
"      Note:",
"     </b>",
"     A multiple dose study in adults suggests reduced renal clearance of verapamil and its metabolite (norverapamil) with advanced renal failure (Storstein, 1984). Additionally, several clinical papers report adverse effects of verapamil in patients with chronic renal failure receiving recommended doses of verapamil (Pritza, 1991; V&aacute;quez, 1996). In contrast, a number of single dose studies show no difference in verapamil (or norverapamil metabolite) disposition between chronic renal failure and control patients (Beyerlein, 1990; Hanyok, 1988; Mooy, 1985; Zachariah, 1991).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Not removed by hemodialysis (Mooy, 1985); supplemental dose is not necessary.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F233869\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In cirrhosis, reduce dose to 20% and 50% of normal for oral and intravenous administration, respectively, and monitor ECG (Somogyi, 1981). The manufacturer of Verelan PM&reg; recommends an initial adult dose of 100 mg/day at bedtime. The manufacturers of Calan&reg;, Calan&reg; SR, Covera-HS&reg;, Isoptin&reg; SR, and Verelan&reg; recommend giving 30% of the normal dose to patients with severe hepatic impairment.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F233831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, sustained release, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calan&reg; SR: 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calan&reg; SR: 180 mg, 240 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, oral, as hydrochloride: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, controlled onset, oral, as hydrochloride: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Verelan&reg; PM: 100 mg, 200 mg, 300 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, sustained release, oral, as hydrochloride: 120 mg, 180 mg, 240 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Verelan&reg;: 120 mg, 180 mg, 240 mg, 360 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 2.5 mg/mL (2 mL, 4 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 40 mg, 80 mg, 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calan&reg;: 80 mg, 120 mg [scored]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as hydrochloride: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, controlled onset, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Covera-HS&reg;: 180 mg [DSC], 240 mg [DSC]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, sustained release, oral, as hydrochloride: 120 mg, 180 mg, 240 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isoptin&reg; SR: 120 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Isoptin&reg; SR: 180 mg, 240 mg [DSC] [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F233816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes caplet (sustained release) and tablet (extended release, controlled onset)",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F233836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Do not crush or chew sustained or extended release products.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Calan&reg; SR, Isoptin&reg; SR: Administer with food.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Verelan&reg;, Verelan&reg; PM: Capsules may be opened and the contents sprinkled on 1 tablespoonful of applesauce, then swallowed immediately without chewing. Do not subdivide contents of capsules.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Rate of infusion: Over 2 minutes; over 3 minutes in older patients (ACLS, 2010)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F233918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 40 10% in NS, dextran 75 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"     <b>",
"      Note:",
"     </b>",
"     Physically compatible in solutions of pH of 3-6, but may precipitate in solutions having a pH &gt;6.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Argatroban, bivalirudin, ciprofloxacin, clonidine, dexmedetomidine, dobutamine, dopamine, eptifibatide, famotidine, fenoldopam, hetastarch in lactate electrolyte injection (Hextend&reg;), hydralazine, inamrinone, linezolid, meperidine, milrinone, nesiritide, oxaliplatin, penicillin G potassium, piperacillin.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Albumin, amphotericin B cholesteryl sulfate complex, ampicillin, nafcillin, oxacillin, pantoprazole, sodium bicarbonate.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aminophylline, propofol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Dimenhydrinate, heparin, inamrinone, milrinone.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Pantoprazole.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F233835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Treatment of hypertension; angina pectoris (vasospastic, chronic stable, unstable) (Calan&reg;, Covera-HS&reg;); supraventricular tachyarrhythmia (PSVT, atrial fibrillation/flutter [rate control])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Supraventricular tachyarrhythmia (PSVT, atrial fibrillation/flutter [rate control])",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F233907\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypertrophic cardiomyopathy; bipolar disorder (manic manifestations)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F233920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Calan&reg; may be confused with Colace&reg;, diltiazem",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Covera-HS&reg; may be confused with Provera&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Isoptin&reg; may be confused with Isopto&reg; Tears",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Verelan&reg; may be confused with Voltaren&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Significant differences exist between oral and I.V. dosing. Use caution when converting from one route of administration to another.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dilacor [Brazil]  may be confused with Dilacor XR brand name for diltiazem [U.S.]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F233909\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (1% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Gingival hyperplasia (&le;19%), constipation (7% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Peripheral edema (1% to 4%), hypotension (3%), CHF/pulmonary edema (2%), AV block (1% to 2%), bradycardia (HR &lt;50 bpm: 1%), flushing (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (2% to 5%), dizziness (1% to 5%), lethargy (3%), pain (2%), sleep disturbance (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Rash (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Dyspepsia (3%), nausea (1% to 3%), diarrhea (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (1%), paresthesia (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Dyspnea (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (4%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oral:",
"     </b>",
"     &le;1%: Abdominal discomfort, alopecia, angina, arthralgia, atrioventricular dissociation, blurred vision, bruising, cerebrovascular accident, chest pain, claudication, confusion, diaphoresis, ECG abnormal, equilibrium disorders, erythema multiforme, exanthema, extrapyramidal symptoms, galactorrhea/hyperprolactinemia, gastrointestinal distress, gynecomastia, hyperkeratosis, impotence, insomnia, macules, MI, muscle cramps, palpitation, psychosis, purpura (vasculitis), shakiness, somnolence, spotty menstruation, Stevens-Johnson syndrome, syncope, tinnitus, urination increased, urticaria, weakness, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      I.V.:",
"     </b>",
"     &lt;1% (Limited to important or life-threatening): Bronchi/laryngeal spasm, depression, diaphoresis, itching, muscle fatigue, respiratory failure, rotary nystagmus, seizure, sleepiness, urticaria, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Asystole, eosinophilia, EPS, exfoliative dermatitis, GI obstruction, hair color change, paralytic ileus, Parkinsonian syndrome, pulseless electrical activity, shock, ventricular fibrillation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F233840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to verapamil or any component of the formulation; severe left ventricular dysfunction; hypotension (systolic pressure &lt;90 mm Hg) or cardiogenic shock; sick sinus syndrome (except in patients with a functioning artificial ventricular pacemaker); second- or third-degree AV block (except in patients with a functioning artificial ventricular pacemaker); atrial flutter or fibrillation and an accessory bypass tract (Wolff-Parkinson-White [WPW] syndrome, Lown-Ganong-Levine syndrome)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     I.V.: Additional contraindications include concurrent use of I.V. beta-blocking agents; ventricular tachycardia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F233820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Conduction abnormalities: Can cause first-degree AV block or sinus bradycardia; other conduction abnormalities are rare. Use is contraindicated in patients with sick sinus syndrome, second- or third-degree AV block (except in patients with a functioning artificial pacemaker), or an accessory bypass tract (eg, WPW syndrome).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension/syncope: Symptomatic hypotension with or without syncope can rarely occur; blood pressure must be lowered at a rate appropriate for the patient's clinical condition.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Increased hepatic enzymes: Rare increases in liver function tests have been observed.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Arrhythmia: Considered contraindicated in patients with wide complex tachycardias unless known to be supraventricular in origin; severe hypotension likely to occur upon administration (ACLS, 2010).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Attenuated neuromuscular transmission: Decreased neuromuscular transmission has been reported with verapamil; use with caution in patients with attenuated neuromuscular transmission (Duchenne's muscular dystrophy, myasthenia gravis); dosage reduction may be required.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heart failure: Avoid use in heart failure; can exacerbate condition. Use is contraindicated in severe left ventricular dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage reduction may be required; monitor hemodynamics and possibly ECG if severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertrophic cardiomyopathy (HCM): Use with caution in patients with HCM with outflow tract obstruction (especially those with high gradients, advanced heart failure, or sinus bradycardia); may be used in patients who cannot tolerate beta-blockade. Verapamil should not be used in those with systemic hypotension or severe dyspnea at rest (Gersh, 2011; Nishimura, 2004).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution; monitor hemodynamics and possibly ECG if severe impairment, particularly if concomitant hepatic impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Agents with SA/AV nodal-blocking properties: Use caution when using verapamil together with a beta-blocker. Administration of I.V. verapamil and an I.V. beta-blocker within a few hours of each other may result in asystole and should be avoided; simultaneous administration is contraindicated. Use with other agents known to reduce SA node function and/or AV nodal conduction (eg, digoxin) or reduce sympathetic outflow (eg, clonidine) may increase the risk of serious bradycardia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digoxin: Verapamil significantly increases digoxin serum concentrations; adjust digoxin dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neuromuscular-blocking agents: May prolong recovery from nondepolarizing neuromuscular-blocking agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: I.V. use for SVT for is not recommended in infants; use with caution in children as myocardial depression/hypotension may occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific  issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Extended-release delivery system (Covera-HS&reg;): Use with caution in patients with severe GI narrowing. In patients with extremely short GI transit times (eg, &lt;7 hours), dosage adjustment may be required; inadequate pharmacokinetic data.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F233905\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2C9 (minor), CYP2E1 (minor), CYP3A4 (major), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP3A4 (moderate), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F233825\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): Verapamil may increase the serum concentration of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Verapamil may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Amiodarone. Sinus arrest has been reported.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anilidopiperidine Opioids: May enhance the bradycardic effect of Calcium Channel Blockers (Nondihydropyridine). Anilidopiperidine Opioids may enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antifungal Agents (Azole Derivatives, Systemic): May enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers. Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antihypertensives: May enhance the hypotensive effect of other Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: May increase the serum concentration of Verapamil. Verapamil may increase the serum concentration of AtorvaSTATin. Management: Consider using lower atorvastatin doses when used together with verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Calcium Channel Blockers may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Avanafil.  Management: The maximum avanafil adult dose is 50 mg per 24-hour period when used together with a moderate CYP3A4 inhibitor.  Patients receiving such a combination should also be monitored more closely for evidence of adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Barbiturates: May increase the metabolism of Calcium Channel Blockers. Management: Monitor for decreased therapeutic effects of calcium channel blockers with concomitant barbiturate therapy. Calcium channel blocker dose adjustments may be necessary. Nimodipine Canadian labeling contraindicates concomitant use with phenobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers: Calcium Channel Blockers (Nondihydropyridine) may enhance the hypotensive effect of Beta-Blockers. Bradycardia and signs of heart failure have also been reported. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Beta-Blockers.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levobunolol; Metipranolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers (Dihydropyridine): May enhance the hypotensive effect of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Calcium Channel Blockers (Dihydropyridine).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May diminish the therapeutic effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: May decrease the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of CarBAMazepine. Management: Consider empiric reductions in carbamazepine dose with initiation of nondihydropyridine calcium channel blockers. Monitor for increased toxic effects of carbamazepine and reduced therapeutic effects of the calcium channel blocker.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cimetidine: May increase the serum concentration of Calcium Channel Blockers. Management: Consider alternatives to cimetidine. If no suitable alternative exists, monitor for increased effects of calcium channel blockers following cimetidine initiation/dose increase, and decreased effects following cimetidine discontinuation/dose decrease.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CloNIDine: May enhance the AV-blocking effect of Calcium Channel Blockers (Nondihydropyridine). Sinus node dysfunction may also be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Clopidogrel: Calcium Channel Blockers may diminish the therapeutic effect of Clopidogrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Colchicine.  Management: Reduce colchicine dose as directed when using with a moderate CYP3A4 inhibitor, and increase monitoring for colchicine-related toxicity.  Use extra caution in patients with impaired renal and/or hepatic function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Moderate): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inhibitors (Strong): May decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: Verapamil may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Consider giving dabigatran 2 hrs before oral verapamil; other dose reductions may be needed. Specific recommendations vary by US vs Canadian labeling, renal function, and indication for dabigatran.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dantrolene: May enhance the hyperkalemic effect of Calcium Channel Blockers (Nondihydropyridine). Dantrolene may enhance the negative inotropic effect of Calcium Channel Blockers (Nondihydropyridine). Management: This interaction has only been described with intravenous dantrolene administration.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Diazoxide: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Disopyramide: Verapamil may enhance the adverse/toxic effect of Disopyramide. Of particular concern is the potential for profound depression of myocardial contractility.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Verapamil may increase the serum concentration of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: Calcium Channel Blockers (Nondihydropyridine) may enhance the AV-blocking effect of Dronedarone. Other electrophysiologic effects of Dronedarone may also be increased. Dronedarone may increase the serum concentration of Calcium Channel Blockers (Nondihydropyridine). Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Dronedarone.  Management: Use lower starting doses of the nondihydropyridine calcium channel blockers (i.e., verapamil, diltiazem), and only consider increasing calcium channel blocker dose after obtaining ECG-based evidence that the combination is being well-tolerated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Eletriptan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Eplerenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Verapamil may increase the bioavailability of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: Verapamil may enhance the bradycardic effect of Fingolimod.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Flecainide: Verapamil may enhance the adverse/toxic effect of Flecainide. In particular, this combination may significantly impair myocardial contractility and AV nodal conduction.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluconazole: May decrease the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Calcium Channel Blockers may increase the serum concentration of Fosphenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Verapamil.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Ivabradine. Ivabradine may enhance the QTc-prolonging effect of Calcium Channel Blockers (Nondihydropyridine). Specifically, the QTc prolonging effects of bepridil may be enhanced. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ivabradine. Specifically, verapamil or diltiazem may increase serum ivabradine concentrations.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg daily in patients also receiving moderate CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: May increase the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lithium: Calcium Channel Blockers (Nondihydropyridine) may enhance the neurotoxic effect of Lithium. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Lithium. Decreased or unaltered lithium concentrations have also been reported with this combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: Verapamil may increase the serum concentration of Lovastatin.  Management: Initiate lovastatin at a maximum adult dose of 10 mg/day, and do not exceed 20 mg/day, in patients receiving verapamil. Monitor closely for signs of HMG-CoA reductase inhibitor toxicity (e.g., myositis, rhabdomyolysis).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Lurasidone.  Management: U.S. labeling: start at 20 mg/day and limit to max of 80 mg/day with moderate CYP3A4 inhibitor.  Canadian labeling: limit to max of 40 mg/day with moderate CYP3A4 inhibitor; avoid concomitant use of grapefruit products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Calcium Channel Blockers. Management: Consider using a noninteracting macrolide. Monitor for increased therapeutic effects of calcium channel blockers if an interacting macrolide antibiotic is initiated, or decreased effects if a macrolide is discontinued.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: Calcium Channel Blockers may enhance the adverse/toxic effect of Magnesium Salts. Magnesium Salts may enhance the hypotensive effect of Calcium Channel Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypotensive effect of Antihypertensives. MAO Inhibitors may enhance the orthostatic hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylphenidate: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midodrine: Calcium Channel Blockers (Nondihydropyridine) may enhance the bradycardic effect of Midodrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May increase the serum concentration of CYP3A4 Substrates. Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nafcillin: May increase the metabolism of Calcium Channel Blockers.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents (Nondepolarizing): Calcium Channel Blockers may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroprusside: Calcium Channel Blockers may enhance the hypotensive effect of Nitroprusside.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Calcium Channel Blockers may increase the serum concentration of Phenytoin.  Management: Monitor for phenytoin toxicity with concomitant use of a calcium channel blocker (CCB) or decreased phenytoin effects with CCB discontinuation. Monitor for decreased CCB therapeutic effects. Nimodipine Canadian labeling contraindicates use with phenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphodiesterase 5 Inhibitors: May enhance the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Moderate) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protease Inhibitors: May decrease the metabolism of Calcium Channel Blockers (Nondihydropyridine). Increased serum concentrations of the calcium channel blocker may increase risk of AV nodal blockade. Management: Avoid concurrent use when possible. If this combination is used, monitor for evidence of toxicity. The manufacturer of atazanavir recommends a 50% dose reduction for diltiazem be considered. Saquinavir or tipranavir use with bepridil is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May enhance the hypotensive effect of Verapamil. Verapamil may increase the serum concentration of QuiNIDine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Ranolazine.  Management: Limit ranolazine dose to a maximum of 500 mg twice daily when used with diltiazem or verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin (and possibly other related compounds) may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May increase the metabolism of Calcium Channel Blockers. This primarily affects oral forms of calcium channel blockers. Management: The labeling for some U.S. and Canadian calcium channel blockers contraindicate use with rifampin however recommendations vary. Consult appropriate labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RisperiDONE: Verapamil may increase the serum concentration of RisperiDONE.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Verapamil may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: Calcium Channel Blockers (Nondihydropyridine) may enhance the anticoagulant effect of Salicylates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Saxagliptin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: Verapamil may increase the serum concentration of Simvastatin.  Management: Avoid concurrent use of verapamil with simvastatin when possible.   If used together, limit adult maximum simvastatin dose to 10 mg/day, and avoid Simcor (simvastatin/niacin) because fixed simvastatin doses in the product exceed this maximum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Calcium Channel Blockers (Nondihydropyridine) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telithromycin: May enhance the hypotensive effect of Verapamil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Vilazodone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Yohimbine: May diminish the antihypertensive effect of Antihypertensives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F233856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Ethanol may increase ethanol levels. Management: Avoid or limit ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Grapefruit juice may increase the serum concentration of verapamil. Management: Avoid grapefruit juice or use with caution and monitor for effects. Calan&reg; SR and Isoptin&reg; SR products should be taken with food or milk; other formulations may be administered without regard to meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease levels of verapamil. Some herbal medications have hypertensive properties (eg, licorice); others may increase or decrease the antihypertensive effect of verapamil. Management: Avoid St John's wort, bayberry, blue cohosh, cayenne, ephedra, ginger, ginseng (American), kola, licorice, and yohimbe. Avoid black cohosh, California poppy, coleus, golden seal, hawthorn, mistletoe, periwinkle, quinine, and shepherd's purse.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F233827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F233843\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In some animal reproduction studies verapamil has been shown to cause fetal harm; adverse maternal effects were also observed. Verapamil crosses the placenta. Although verapamil is not considered a major human teratogen, use during pregnancy may cause adverse fetal effects (bradycardia, heart block, hypotension).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F233873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended (AAP considers &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F233844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Crosses into breast milk; manufacturer recommends to discontinue breast-feeding while taking verapamil.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F233845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calan&reg; SR and Isoptin&reg; SR products may be taken with food or milk, other formulations may be administered without regard to meals; sprinkling contents of Verelan&reg; or Verelan&reg; PM capsule onto applesauce does not affect oral absorption.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F233842\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Verapamil HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $195.84",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $130.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $135.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $252.23",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $152.54",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $366.98",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (100): $209.94",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Verelan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $578.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $605.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $683.41",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     360 mg (100): $1004.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, 24-hour",
"     </b>",
"     (Verelan PM Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $467.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $602.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     300 mg (100): $875.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Verapamil HCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2.5 mg/mL (2 mL): $4.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Calan SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $320.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $406.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $464.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Isoptin SR Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $219.58",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $278.31",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $318.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Verapamil HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $107.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     180 mg (100): $143.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     240 mg (100): $163.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Calan Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $176.92",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $239.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Verapamil HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (100): $27.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80 mg (100): $36.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     120 mg (100): $47.22",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F233829\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor blood pressure and heart rate; periodic liver function tests; ECG, especially with renal and/or hepatic impairment",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F233846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anpec (AU, TW);",
"     </li>",
"     <li>",
"      Beaptin SR (SG);",
"     </li>",
"     <li>",
"      Calaptin (IN);",
"     </li>",
"     <li>",
"      Cardiolen (CN);",
"     </li>",
"     <li>",
"      Caveril (AE, BB, BH, BM, BS, BZ, CY, ET, GH, GY, IL, JM, JO, KE, LB, MU, OM, PR, QA, SR, SY, TT, TZ, YE);",
"     </li>",
"     <li>",
"      Cordilat (BR);",
"     </li>",
"     <li>",
"      Cordilox SR (AU);",
"     </li>",
"     <li>",
"      Cronovera (MX);",
"     </li>",
"     <li>",
"      Devincil (LU);",
"     </li>",
"     <li>",
"      Dilacoran (BR, MX);",
"     </li>",
"     <li>",
"      Fibrocard (LU);",
"     </li>",
"     <li>",
"      Flamon (BB, BM, BS, BZ, CH, GY, JM, MY, PR, SR, TT);",
"     </li>",
"     <li>",
"      Geangin (NL);",
"     </li>",
"     <li>",
"      Hexasoptin (DK, FI);",
"     </li>",
"     <li>",
"      Ikacor (IL);",
"     </li>",
"     <li>",
"      Ikapress (IL);",
"     </li>",
"     <li>",
"      Isoptin (AT, AU, BG, CH, CO, CZ, DE, DK, EC, EE, FI, GR, HK, HR, HU, ID, IE, IT, KP, LU, MY, NL, NO, NZ, PE, PH, PK, PL, PT, RU, SE, SG, TR, ZA);",
"     </li>",
"     <li>",
"      Isoptin Retard (AT, CH, CR, DE, DO, EE, FI, GR, GT, HN, IT, NI, PA, PL, PT, SE, SV);",
"     </li>",
"     <li>",
"      Isoptin SR (AU, BG, CL, CZ, HK, KP, NL, NZ, SG, TW, ZA);",
"     </li>",
"     <li>",
"      Isoptine (BE, FR);",
"     </li>",
"     <li>",
"      Isoptino (AR, PY, UY);",
"     </li>",
"     <li>",
"      Lekoptin (HR);",
"     </li>",
"     <li>",
"      Librapamil (EC);",
"     </li>",
"     <li>",
"      Manidon (ES, VE);",
"     </li>",
"     <li>",
"      Manidon Retard (ES);",
"     </li>",
"     <li>",
"      Quasar (IT);",
"     </li>",
"     <li>",
"      Securon (GB, IE);",
"     </li>",
"     <li>",
"      Vasomil (ZA);",
"     </li>",
"     <li>",
"      Vasopten (IN);",
"     </li>",
"     <li>",
"      Veracaps SR (AU);",
"     </li>",
"     <li>",
"      Verahexal (DE, LU);",
"     </li>",
"     <li>",
"      Veraloc (DK);",
"     </li>",
"     <li>",
"      Veramex (DE);",
"     </li>",
"     <li>",
"      Veramil (IN);",
"     </li>",
"     <li>",
"      Verapamil Hydrochloride (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Verapamil Pharmavit (HU);",
"     </li>",
"     <li>",
"      Verapress 240 SR (IL);",
"     </li>",
"     <li>",
"      Veratad (CO);",
"     </li>",
"     <li>",
"      Verelan (PH);",
"     </li>",
"     <li>",
"      Verisop (IE);",
"     </li>",
"     <li>",
"      Vermine (TH);",
"     </li>",
"     <li>",
"      Verpamil (AE, BH, CY, EG, HU, IL, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Vetrimil (TW);",
"     </li>",
"     <li>",
"      Zolvera (GB, IE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F233819\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits calcium ion from entering the &ldquo;slow channels&rdquo; or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarization; produces relaxation of coronary vascular smooth muscle and coronary vasodilation; increases myocardial oxygen delivery in patients with vasospastic angina; slows automaticity and conduction of AV node.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F233839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Peak effect: Oral: Immediate release: 1-2 hours; I.V.: 1-5 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: Oral: Immediate release tablets: 6-8 hours; I.V.: 10-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3.89 L/kg (Storstein, 1984)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~90%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic (extensive first-pass effect) via multiple CYP isoenzymes; primary metabolite is norverapamil (20% pharmacologic activity of verapamil)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Oral: 20% to 35%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Infants: 4.4-6.9 hours; Adults: Single dose: 3-7 hours, Multiple doses: 4.5-12 hours; severe hepatic impairment: 14-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, serum: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate release: 1-2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Extended release (Covera-HS&reg;, Verelan PM&reg;): ~11 hours, drug release delayed ~4-5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sustained release: 5.21 hours (Calan&reg; SR, Isoptin&reg; SR); 7-9 hours (Verelan&reg;)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (70% as metabolites, 3% to 4% as unchanged drug); feces (16%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, &ldquo;Transfer of Drugs and Other Chemicals Into Human Milk,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson JL, Adams CD, Antman EM, et al, \"2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(18):e426-579.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/21444888/pubmed\" id=\"21444888\" target=\"_blank\">",
"        21444888",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Antman EM, Anbe SC, Alpert JS, et al, &ldquo;ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2004, 110(5):588-636.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/15289388/pubmed\" id=\"15289388\" target=\"_blank\">",
"        15289388",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Aronow WS, Fleg JL, Pepine CJ, et al, &ldquo;ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123(21):2434-506.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/21518977/pubmed\" id=\"21518977\" target=\"_blank\">",
"        21518977",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beyerlein C, Csaszar G, Hollmann M, et al, &ldquo;Verapamil in Antihypertensive Treatment of Patients on Renal Replacement Therapy -- Clinical Implications and Pharmacokinetics,&rdquo;",
"      <i>",
"       Eur J Clin Pharmacol",
"      </i>",
"      , 1990, 39(Suppl 1):35-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/2261942/pubmed\" id=\"2261942\" target=\"_blank\">",
"        2261942",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Black HR, Elliott WJ, Grandits G, et al, &ldquo;Principal Results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(16):2073-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/1270946/pubmed\" id=\"1270946\" target=\"_blank\">",
"        1270946",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Braunwald E, Antman EM, Beasley JW, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2002, 40(7):1366-74.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/12383588/pubmed\" id=\"12383588\" target=\"_blank\">",
"        12383588",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chobanian AV, Bakris GL, Black HR, et al, &ldquo;The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(19):2560-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/12748199/pubmed\" id=\"12748199\" target=\"_blank\">",
"        12748199",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chow T, Galvin J, and McGovern B, &ldquo;Antiarrhythmic Drug Therapy in Pregnancy and Lactation,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1998, 82(4A):58I-62I.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/9737655/pubmed\" id=\"9737655\" target=\"_blank\">",
"        9737655",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Effect of Verapamil on Mortality and Major Events After Acute Myocardial Infarction. The Danish Verapamil Infarction Trial II-DAVIT II,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1990, 66(10):779-85.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/2220572/pubmed\" id=\"2220572\" target=\"_blank\">",
"        2220572",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122 (18 Suppl 3):640-56.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/20956217/pubmed\" id=\"20956217\" target=\"_blank\">",
"        20956217",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fihn SD, Gardin JM, Abrams J, et al, &ldquo;2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(25):3097-137.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/23166211/pubmed\" id=\"23166211\" target=\"_blank\">",
"        23166211",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuster V, Ryden LE, Cannom DS, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation-Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Developed in Collaboration With the European Heart Rhythm Association and the Heart Rhythm Society,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2006, 48(4):854-906.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/16904574 /pubmed\" id=\"16904574 \" target=\"_blank\">",
"        16904574",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gersh BJ, Maron BJ, Bonow RO, et al, &ldquo;2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(24):e783-831.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/22068434/pubmed\" id=\"22068434\" target=\"_blank\">",
"        22068434",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Gibbons RJ, Abrams J, Chatterjee K, et al, &ldquo;ACC/AHA 2002 Guideline Update for the Management of Patients With Chronic Stable Angina - Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina),&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 41(1):159-68.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/12570960/pubmed\" id=\"12570960\" target=\"_blank\">",
"        12570960",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hanyok JJ, Chow MS, Kluger J, et al, &ldquo;An Evaluation of the Pharmacokinetics, Pharmacodynamics, and Dialyzability of Verapamil in Chronic Hemodialysis Patients,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1988, 28(9):831-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/3230150/pubmed\" id=\"3230150\" target=\"_blank\">",
"        3230150",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lichtenwalner MR, Mencken T, Tully R, et al, &ldquo;False-Positive Immunochemical Screen for Methadone Attributable to the Metabolites of Verapamil,&rdquo;",
"      <i>",
"       Clin Chem",
"      </i>",
"      , 1998, 44(5):1039-41.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/9590378/pubmed\" id=\"9590378\" target=\"_blank\">",
"        9590378",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Magee LA, Schick B, Donnenfeld AE, et al, &ldquo;The Safety of Calcium Channel Blockers in Human Pregnancy: A Prospective, Multicenter Cohort Study,&rdquo;",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1996, 174(3):823-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/8633650/pubmed\" id=\"8633650\" target=\"_blank\">",
"        8633650",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Maron BJ, McKenna WJ, Danielson GK, et al, &ldquo;American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy. A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2003, 42(9):1687-713.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/14607462/pubmed\" id=\"14607462\" target=\"_blank\">",
"        14607462",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mooy J, Schols M, v Baak M, et al, &ldquo;Pharmacokinetics of Verapamil in Patients With Renal Failure,&rdquo;",
"      <i>",
"       Eir J Clin Pharmacol",
"      </i>",
"      , 1985, 28(4):405-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/4029246/pubmed\" id=\"4029246\" target=\"_blank\">",
"        4029246",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Neumar RW, Otto CW, Link MS, et al, &ldquo;Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2010, 122(18 Suppl 3):729-67.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nishimura RA and Holmes DR Jr, &ldquo;Clinical Practice. Hypertrophic Obstructive Cardiomyopathy,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2004, 350(13):1320-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/15044643/pubmed\" id=\"15044643\" target=\"_blank\">",
"        15044643",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      O'Gara PT, Kushner FG, Ascheim DD, et al, \"2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,\"",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 127(4):e362-425.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/3247304/pubmed\" id=\"3247304\" target=\"_blank\">",
"        3247304",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Pritza DR, Bierman MH, and Hammeke MD, \"Acute Toxic Effects of Sustained-Release Verapamil in Chronic Renal Failure,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 1991, 151(10):2081-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/1843183/pubmed\" id=\"1843183\" target=\"_blank\">",
"        1843183",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rengo F, Carbonin P, Pahor M, et al, &ldquo;A Controlled Trial of Verapamil in Patients After Acute Myocardial Infarction: Results of the Calcium Antagonist Reinfarction Italian Study,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1996, 77(5):365-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/8602564/pubmed\" id=\"8602564\" target=\"_blank\">",
"        8602564",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Skanes AC, Healey JS, Cairns JA, et al, &ldquo;Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,&rdquo;",
"      <i>",
"       Can J Cardiol",
"      </i>",
"      , 2012, 28(2):125-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/22433576/pubmed\" id=\"22433576\" target=\"_blank\">",
"        22433576",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Somogyi A, Albrecht M, Kliems G et al, &ldquo;Pharmacokinetics, Bioavailability and ECG Response of Verapamil in Patients With Liver Cirrhosis,&rdquo;",
"      <i>",
"       Br J Clin Pharmacol",
"      </i>",
"      , 1981, 12(1):51-60.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/7248141 /pubmed\" id=\"7248141 \" target=\"_blank\">",
"        7248141",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Storstein L, Larsen A, Midtbo K, et al, &ldquo;Pharmacokinetics of Calcium Channel Blockers in Patients With Renal Insufficiency and in Geriatric Patients,&rdquo;",
"      <i>",
"       Acta Med Scand Suppl",
"      </i>",
"      , 1984, 681:25-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/6587753/pubmed\" id=\"6587753\" target=\"_blank\">",
"        6587753",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      V&aacute;quez C, Huelmos A, Alegr&iacute;a E, et al, &ldquo;Verapamil Deleterious Effects in Chronic Renal Failure,&rdquo;",
"      <i>",
"       Nephron",
"      </i>",
"      , 1996, 72(3):461-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/8852497/pubmed\" id=\"8852497\" target=\"_blank\">",
"        8852497",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Verapamil in Acute Myocardial Infarction. Danish Multicenter Study Group on Verapamil in Myocardial Infarction,&rdquo;",
"      <i>",
"       Am J Cardiol",
"      </i>",
"      , 1984, 54(11):24E-28E.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/6391136/pubmed\" id=\"6391136\" target=\"_blank\">",
"        6391136",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wann SL, Curtis AB, January CT, et al, &ldquo;2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Updating the 2006 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 123 (1):104-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/21173346/pubmed\" id=\"21173346\" target=\"_blank\">",
"        21173346",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Zachariah PK, Moyer TP, Thoebald HM, et al, &ldquo;The Pharmacokinetics of Racemic Verapamil in Patients With Impaired Renal Function,&rdquo;",
"      <i>",
"       J Clin Pharmacol",
"      </i>",
"      , 1991, 31(1):45-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?9/18/9514/abstract-text/2045528/pubmed\" id=\"2045528\" target=\"_blank\">",
"        2045528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10043 Version 54.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-183.166.191.243-B4DFEB0FC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9514=[""].join("\n");
var outline_f9_18_9514=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233861\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233862\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233911\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233866\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9729804\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233867\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233868\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233869\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233831\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233816\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233836\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233918\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233835\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233907\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233920\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233909\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233840\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233820\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233905\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233825\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233856\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233827\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233843\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233873\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233844\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233845\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233842\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233829\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233846\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233819\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F233839\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10043\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10043|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?5/53/5974?source=related_link\">",
"      Verapamil: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/3/33849?source=related_link\">",
"      Verapamil: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_18_9515="Clinical risk factors for overuse tendinopathy";
var content_f9_18_9515=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F55764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F55764&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical risk factors for overuse tendinopathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Intrinsic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Increased body mass index (BMI)&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Biomechanical abnormalities",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior tendon lesions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fluoroquinolone use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Extrinsic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Training errors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Environmental conditions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor ergonomics",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9515=[""].join("\n");
var outline_f9_18_9515=null;
var title_f9_18_9516="Rx guide radiation exposure";
var content_f9_18_9516=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F57598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F57598&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment guidelines for radiation exposure",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Variable",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cytokines",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotics",
"       </td>",
"       <td class=\"subtitle1\">",
"        HCT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        Less than 100",
"casualties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Healthy, no other injuries",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3 to 10*",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        2 to 10",
"       </td>",
"       <td>",
"        Allo: 7 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Auto: 4 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple injuries or burns",
"       </td>",
"       <td>",
"        2 to 6",
"       </td>",
"       <td>",
"        2 to 6",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\" rowspan=\"1\">",
"        More",
"than 100 casualties",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Healthy, no other injuries&nbsp;",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        3 to 7",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        2 to 7",
"       </td>",
"       <td>",
"        Allo: 7 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Auto: 4 to 10",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Multiple injuries or burns",
"       </td>",
"       <td>",
"        2 to 6",
"       </td>",
"       <td>",
"        2 to 6",
"       </td>",
"       <td>",
"        NA",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HCT: hematopoietic cell transplantation; Allo: allogeneic HCT; Auto: autologous HCT; NA: not applicable; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macroplage colony-stimulating factor.",
"     <br>",
"      * This table provides a consensus guideline for treatment with cytokines (eg, G-CSF, GM-CSF), antibiotics, and consideration for hematopoietic cell transplantation based upon whole body or significant partial body exposure doses, given in Gy units. See text for treatment details.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Modified with permission from: Waselenko JK, MacVittie TJ, Blakely WF, et al. Medical management of the acute radiation syndrome: Recommendations of the strategic national stockpile radiation working group. Ann Int Med 2004; 140:1039. Copyright &copy; 2004 American College of Physicians.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9516=[""].join("\n");
var outline_f9_18_9516=null;
var title_f9_18_9517="Cause pain by location";
var content_f9_18_9517=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F71415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F71415&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Location of pain of some of the common diseases that cause acute pelvic pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Periumbilical pain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          All visceral diseases in their early stages",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abdominal trauma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Abdominal wall hernias",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bowel obstruction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Diffuse or generalized pain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          All visceral pathologies late in their course",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pelvic inflammatory disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endometriosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Muscular strain or sprain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Bowel obstruction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Left lower quadrant",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adnexal torsion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Constipation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Crohn's disease",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diverticulitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ectopic pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endometriosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Inflammation or perforation of colonic carcinoma",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Irritable bowel syndrome",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ovarian cyst or ruptured ovarian cyst",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pyelonephritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salpingitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urinary calculi",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Right lower quadrant",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Appendicitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ectopic pregnancy",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Adnexal torsion",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Ovarian cyst or ruptured ovarian cyst",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urinary calculi",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Endometriosis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pyelonephritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Meckel diverticulitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Regional enteritis (Crohn's disease)",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Salpingitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Suprapubic pain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Obstruction of the urinary bladder",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cystitis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urinary calculi",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Lumbar radiation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Colonic obstruction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Pyelonephritis",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urinary calculi",
"         </td>",
"        </tr>",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Flank pain",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Urinary calculi",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Howard, FM. Acute Abdominal Pain. In: Primary Care for Women., Leppert, PC, Peipert, P (Eds), Lippincott, Williams and Wilkins 2004. Copyright &copy;2004 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9517=[""].join("\n");
var outline_f9_18_9517=null;
var title_f9_18_9518="Questionnaire sleep driving";
var content_f9_18_9518=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F76362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F76362&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 574px\">",
"   <div class=\"ttl\">",
"    Patient questionnaire - sleepiness while driving",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 554px; height: 209px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9518=[""].join("\n");
var outline_f9_18_9518=null;
var title_f9_18_9519="Snuffbox palpation";
var content_f9_18_9519=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F78551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F78551&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Snuffbox palpation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 310px; height: 327px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The wrist is placed in neutral position, radial side up. Downward pressure is applied just proximal to the carpometacarpal joint of the thumb. With firm pressure applied to the anatomic snuff box, the rounded distal portion of the scaphoid (navicular) can be felt when the wrist is passively ulnar deviated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_18_9519=[""].join("\n");
var outline_f9_18_9519=null;
